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8A I M A N D S C 0 P E
Cancer is the number one killer in Hong Kong and in many
parts of the world. Conventional modalities for the treatment
of cancer such as surgery, radiotherapy and chemotherapy have
many limitations and often accompanied with severe side
effects in curing cancer. In the last two decades or so,
there has been substantial advances in our understanding on
the role of immune mechanisms capable of non-specifically or
specifically eliminating malignant cells. However,
experimental data so far accumulated indicate that the immune
reactions to tumours are by no means simple. There are
obviously many factors that serve to modify, limit or
regulate the immune responses in tumour-bearing animals and
humans. The aim of this thesis project is to dissect out the
complex effector and regulatory mechanisms operative in
immune responses of mice to an experimental syngeneic tumour.
In addition, attempts will also be made to study the
therapeutic efficacy of natural products in 'tumour-bearing
host. it is conceivable that we would gain a better insight
into the immunological factors that restraint tumour growth
and development.
In order to investigate the host anti-tumour response
and to study the immunol-ogical functions in a tumour-bearing
host, the MBL-2 tumour (Moloney leukemia virus-induced T cell
lymphoma) in C57BL/6J mice was chosen as an experimental
animal-tumour model. In this project, several aspects were
examined. These included the evaluation of the non-specific
9and specific cell-mediated immune responses in mice bearing
MBL-2 tumour, the studies on MBL-2-induced immunosuppression
in its host, and.finally, the use of natural products or
immunomodifiers in therapeutic treatment of mice
bearing MBL-2 tumour.
The philosophy of this project is to enlarge our
understanding on the role of immunity in controlling tumour
growth and metastasis, with the view that manipulating the
immunological mechanisms may have the potential application
for the immunoprophylaxis and immunotherapy of human cancer.
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ABSTRACT
In order to investigate the role of immunity in
controlling the growth of tumour and to study the
immunodysfunctions in a tumour-bearing host, C57BL/6J mice
with one of its syngeneic tumours, MBL-2 (Moloney leukemia
virus-induced T cell lymphoma), were selected as an
experimental animal-tumour model. It was found that
subcutaneous inoculation of 2 x 105 MBL-2 tumour cells
caused significant metastatic spread of tumour to other
organs such as spleen and liver 12 days after tumour
challenge. It also resulted in the death of host within 23
days. The immunogenicity of MBL-2 tumour was demonstrated as
mice immunized with mitomycin C-treated tumour resisted
subsequent challenge with the same viable tumour. In
addition, in vitro stimulation of normal splenocytes with
mitomycin C-treated tumour resulted in the generation of
effector cells which exhibited specific cytotoxicity towards
MBL-2 target in vitro. Studies on the role of non-specific
immune mechanisms in the defence of mice against MBL-2 tumour
showed that C. parvum-activated or picolinic acid-activated
macrophages exhibited significant cytotoxicity against MBL-2
cells in vitro, and indicated that activated macrophages may
be protective in vivo. Although various preparations of MBL-2
antigen(s) were found to be capable augmenting natural killer
(NK) activity in vivo, yet the data showed that MBL-2 tumour
itself was a poor target for NK cell-mediated killing in
vitro. Moreover, the. MBL-2 cells also failed to sensitize for
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and to elicit a tumour-specific delayed type hypersensitivity
(DTH) response in its host.
Different parameters of the immune functions*of the host
were also monitored during tumour progression in MBL-2-
bearing mice. The result showed that a wide variety of
immunological functions were strongly depressed in tumour-
bearing host. These included: (i) the lymphoproliferative
responses of splenocytes to T and B cell mitogens (ii) the
production of antibodies against heterologous sheep
erythrocytes (SRBC) (iii) the induction of a DTH response to
SRBC and also (iv) the in vitro production of interleukin-2
(IL-2) from Con A-activated splenocytes. Depression of these
four immune parameters was found to be positively correlated
with the duration of tumour growth, i.e., the longer was the
time after tumour inoculation, the weaker were the immune
responses elicited. However, the cytotoxicity of NK cells and
the phagocytic activity of macrophages were not appreciably
suppressed in mice bearing MBL-2 tumour. Furthermore,
suppressor cells and suppressive factors were also found in
spleen and body fluids (serum and peritoneal exudate fluid)
respectively in tumour-bearing mice.
In a preliminary attempt to study the therapeutic
efficacy of drugs in the treatment of MBL-2 tumour in its
syngeneic host, three different natural products or
immunomodifiers, which included gossypol, tumour necrosis
factor-containing serum and interleukin-2, were evaluated for
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their cytotoxicity against MBL-2 cells in vitro and/or their
growth-inhibitory effect against MBL-2 tumour in vivo. The
results, when taken together, indicated that gossypol was
highly cytotoxic to MBL-2 cell in vitro whereas IL-2
demonstrated significant anti-tumour activity in vivo.
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1Cancer is not a single disease but a group of diseases
that are expressed as the abnormal, continued and
uncontrolled growth of cells of a given tissue. Cancer occurs
at only one site or spread out to other distal sites
(metastasis).. The development of cancer and the factors that
regulate neoplastic growth are ill-defined. In this chapter,
the roles of host immune mechanisms in controlling the growth
and development of tumour will be reviewed. Because of the
vast literature in this area, the discussion that follows is
neither comphrensive nor referenced in details. Only those
topics that are most pertinent to the work done in this
thesis will be highlighted.
1.1. TUMOUR ANTIGENS
For a tumour to initiate an immunological response in
its host, it must have distinctive antigen(s) which can be
recognized by the host's immune system as foreign. During the
initial works in tumour immunology, the tumour antigens were
not defined in outbred animal system. Foley in 1953 (Foley,
1953) produced the first evidence to show the existence of
tumour-specific antigens in syngeneic animal-tumour system
and initiated the use of inbred mice as the experimental
model.
Tumour antigens can be grouped into two main subclasses:
tumour-specific antigens (TSA) and tumour-associated antigens
• (TAA).
2(A) Tumour-Specific Antigens (TSA)
Antigens which can only be detected on tumour
cell-surface and do not exist on the non-neoplastic
tissue may properly regarded as tumour-specific. Of
course, it should be aware that defining an antigen as
TSA is essentially based on the techniques used and the
control tissue selected. If either the techniques used
are not sensitive to detect the trace amount of antigens
on normal tissue or the selected normal tissue is not
appropriate, the antigen type determined may be
misleading
(B) Tumour-Associated Antigens (TAA)
TAA is defined as the antigen that can be detected
both on tumour cells and normal tissue. For examples,
oncodevelopmental (OD) tumour markers, including
carcinoembryonic antigens (CEA) (Gold and Freedman,
1965), alphafetoprotein (Abelev, 1974) and
oncodevelopmental tumour antigens, are the known TAA.
Tumour-associated transplantation antigens (TATA) are
defined by their ability to protect pre-immunized animals
against subsequent challenge with the same tumour. They are
also known as tumour rejection antigens (TRA) and tumour-
specific transplantation antigens (TSTA). TATA are localized
on the plasma membrane and evoke the immunological reactions
and act as targets for immune attack (Moller and Moller,
1976).
31.1.1. ANTIGENS OF CHEMICALLY-INDUCED TUMOURS
From mid-1950s, many tumours have been induced in
rodents by chemical carcinogens (Foley, 1953 Baldwin, 1955
Prehn and Main, 1957). Prehn and his co-workers showed that
transplantation resistance induced in the strain of origin
was tumour-specific. For example, the rejection responses
elicited by 3-methylcholanthrene-(MC) induced sarcoma are
variable in the same strain, and more marked between
different species (rat and pig) (Oettgen et al., 1968
Baldwin, 1973). However, the unique TATA is demonstrated.
Some cross-reacting antigens are also found but it may be
only due to antigenic conversion that is caused by type C
virus (Stuck et al., 1964a). The cross-reacting TAA may also
exist but they are not important in tumour rejection process.
Besides TATA, tumour-associated antigens (TAA) are also
found in chemically-induced tumours (Steele and Sjogren,
1974 Steele et al., 1975). The genetic origin of TATA of
chemically-induced tumours has not yet known. It has been
proposed that TATA originate from a mutation-like alteration
with direct or indirect interaction of oncogenic agent with
cellular DNA. TATA share many common features with normal
histocompatibility antigens, including their high degree of
polymorphism (Basombuo, 1970 Graff and Bailey, 1973), cell
surface location and mobility (Yefenof and Klein, 1974),
molecular weight and amino acid composition (Canty and
Wunderlich, 1971) and capacity to induce immune responses
((anty andunderlich. 1971). In addition. an inverse
4relationship is found between the expression of H-2 and TATA
in MC-induced murine sarcoma. Based on these observations,
whether TATA are newly formed antigens or only a
rearrangement of H-2 antigen is still a mystery and many
contradictory events were reported (Bowen and Baldwin, 1975
Klein and Klein, 1975 Parmiani and Invernizzi, 1975).
1.1.2. ANTIGENS OF VIRUS-INDUCED TUMOURS
(I) Oncodnaviruses
Many viruses have a strong association with human
neoplasia. For instance, Epstein-Barr virus (EBV) and
Burkitt's lymphoma (Klein, 1975) and Herpes simplex
virus type 2 and cervical carcinoma (Rapp, 1974). The
virus-cell interaction may lead to production of new
virus virion (V) antigens and cytolysis or abortive
infection resulting in malignant transformation. The
antigens induced by DNA viruses in neoplastic cells are
not structural proteins and differ from virion antigens.
Virus-induced antigens that can elicit immune responses
in the host are classified into three types according to
their cellular location, which include nuclear,
cytoplasmic or cell-surface antigens (Tevethia and
Tevethia, 1975).
TATA in the transformed cells that evoke humoral
and cellular immune responses in the host are all
located on cell surface and are common for all neoplasms
that are induced by the same virus. The TATA are quite
5stable during the prolonged transplantation and also
unique in same virus-induced tumours of widely different
histological type. They also have no cross-reaction with
other tumours induced by different unrelated viruses.
Since these tumour antigens are different from the
virion antigens, their genetic origin is still a
mystery. Whether the TATA are coded by virus genome or
originated from host cells is still open for discussion
(Coggin and Anderson, 1974 Tevethia and Tevethia,
1975.
(II) Oncornaviruses
Oncogenic RNA viruses are markedly different from
oncogenic DNA viruses in structure and also replication
pattern. Generally, RNA virus-transformed cells are
permissive and continuously producing infectious virus.
Both cellular and viral antigens are expressed on
neoplastic cells. For example, the virion antigens of
murine leukemia virus (MuLV) are divided into viral
envelope antigens (VEA) and intraviral antigens (Aoki
and Sibal, 1975). Virus also induces cellular antigens
which may locate on cell surface as TATA, VEA or
intracellular intraviral antigens. Soluble antigens
(Stuck et al., 1964b Aoki and Sibal, 1975) are also
detected in circulation and kidney in form of immune
complex (Mellors et al., 1971 Hollis et al., 1974).
61.1.3. ANTIGENS OF SPONTANEOUS TUMOURS
Both chemically- and viral-induced tumours have their
own TSTA and generate specific immune responses in their
hosts. However, the spontaneous tumours cannot induce any
immune response in their syngeneic hosts and the absence of
antigenicity may also favour the growth of tumour and escape
from the immune surveillance (Brodt, 1983).
1.1.4. ONCODEVELOPMENTAL (OD) TUMOUR MARKERS
Many products that are very common to developing and
mature tumours, but rarely found in normal tissue, have been
found. Among them, oncodevelopmental transplantation antigen,
carcinoembryonic antigen and alphafetoprotein are
particularly important.
.(I) Oncodevelopmental transplantation antigen (ODTA)
Tumours and fetal tissue may share antigens that are
different from TSTA. Oncodevelopmental antigens are not
specific for a given tumour but are shared by tumours of
different histologic.. type and even of different species of
origin. However, the ODTA only play a minor role in the
tumour rejection response (Baldwin et al., 1974).
(II) Carcinoembryonic antigens (CEA)
CEA is not immunogenic in the primary host but since it
was identified by using antisera obtained by immunization of
other species, it was, therefore, called antigens. CEA was
firstly identified in cancers of the gastrointestinal tract
and also detected in the sera of patients with various
7neoplastic and non-neoplastic diseases. Thus, it is not a
diagnostic parameter for cancer but an elevated CEA level in
serum may indicate a recurrence of growth or metastasis.
(III) Alphafetoprotein (AFP)
AFP is a serum protein which is rapidly secreted from
the cell and is found in high concentrations in fetal sera,
maternal sera and in the sera of adults with hepatomas. It is
also a glycoprotein with molecular weight of 60,000 and
contains 4% carbohydrates. The elevated AFP concentration in
tumour-bearing host is highly related to the tumours of liver
or yolk sac and rare with tumours arising from
embryologically unrelated tissues.
In the point of antigenic expression, tumours are very
,heterogeneous and also consist of various subpopulations with
diverse immunogenic capacities. The c-omplexity of tumour
antigenicity may relate to their growth properties and the
host's immune system.
1.2. IMMUNE SURVEILLANCE THEORY
The concept of immunological surveillance was first
proposed by Ehrlich in 1908, then rearranged by Thomas (1959)
and finally developed by Burnet (1971). The concept stated
that the normal immune functions, or more precisely, the
thymus-derived (T) lymphocytes in the cellular immune system,
can recognize and destroy the newly formed tumour cell in
situ. This concept has been critically reviewed by many
8scientists (Melief and Schwartz, 1975 Stutman, 1975 Moller
and Moller, 1976 Prehn, 1976 Grossman and Herberman, 1986).
Actually, from many evidences that collected from- various
sources, the immune surveillance theory should be frequently
revised. Among those evidences, the study of cellular origin
of tumours provides the strongest argument.
Myelomas (Friedmann and Fialkow, 1976) arise from B-
lymphocytes and generate a large scale of homogeneous
immunoglobulin. All immunoglobulins (Ig) belong to the same
class and have the same variable regions. It indicates that
all myelomas are' derived from one single cell.
Monoclonality is not only found in myeloma but also other
tumours such as non-Hodgkin lymphoma, Burkitt's lymphoma and
chronic lymphosarcoma leukaemia in human. In animal system,
Abelson's virus myelomas (Potter et al., 1973) and Gross
virus-induced T cell leukaemias in AKR mice are also
monoclonal. Chemically induced sarcomas are also shown to be
monoclonal because they have unique TATA which have no cross-
reactivity with other tumours. This is also shown by the
studies of Prehn (1970) who used the methylcholanthrene-
induced tumours, and compared the TATA in opposite poles of
the same tumour mass. If the tumour origin was multicellular,
cells from opposite sites should have different TATA.
However, the results showed that the TATA were unique for the
cells. Thus, monoclonal origin of tumour was suggested for
most, if not all, of the tumours.
The most likely mechanism for the monoclonal origin is
9that carcinogens only accelerate the occurrence of rare
genetic changes during replications and repairs. These
changes will cause errors that will be accumulated and
eventually induce the appearance of monoclonal tumour.
Besides, many clinical and experimental observations
also showed that the predictions of immune surveillance are
not all valid. For examples, in those immunosuppressive
individuals, the tumours generated or regrowth are monoclonal
rather than polyclonal. Moreover, Heidelberger and Prehn
(Moller and Moller, 1978) also found that tumours generated
in vitro have much weaker antigenicity than that expected by
immune surveillance. Nevertheless, the concept of immune
surveillance somehow provides logical explanations for many
events that are observed in the field of tumour immunology.
Of course, another theory is required to explain those
contradictory events.
1.3. HOST IMMUNE MECHANISMS IN THE CONTROL OF TUMOUR GROWTH
AND METASTASIS
It is well-known that the immune system is composed of
many interacting networks involving many different components
in humoral and cellular branches. The final result is the
destruction or elimination of pathogens. It may also generate
immunological memory so that the host will respond much
faster in the second confrontation of the same antigen. On
the other hand, it may lead to the development of
immunological tolerance and suppression. For anti-tumour
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responses, the immune system may also play these dual roles
that it may try to eliminate or destroy the tumour cells on
one end whilst it may also facilitate the growth and
metastasis of tumour mass on the other end (Beverley, 1978
Naor, 1979). Figure 1.1. depicts the complexity of the host
immunologic responses to tumour. It can be seen that tumour
antigens can interact with all the major cell types of the
immune system (i.e. macrophages, T and B lymphocytes), and
these result in a series of cellular reactions and
interactions and lead to the elaboration of a wide variety of
lymphokines and monokines. Thus, the immunological studies of
tumour-host relationship are by no means simple and our
knowledge of which is continually expanding and evolving. In
order to illustrate the role of immune system in influencing
tumour growth and metastasis, both cell-mediated and humoral
immune mechanisms in response to tumours will be discussed.
1.3.1. CELL-MEDIATED IMMUNITY
(I) THYMUS-DERIVED LYMPHOCYTES
It is well-established that thymus-derived (T)
lymphocytes .are the major cell group related to the cell'-
mediated immunity and can be subclassified into four groups:
helper T cells, suppressor T cells, cytotoxic T cells and
delayed type hypersensitivity (DTH) T cells. To activate the
T cell population, the T-cell-dependent antigens are
presented to T helper cells by antigen-presenting cells (APC)
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Fig. 1.1. Immunologic Mechanisms Involved in Tumour Growth and Destructioi
(Modified from Siegel B.V. (1985).)
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Macrophages (also served as APC) secrete interleukin-1 (IL-1)
which activates the proliferation of T cells. After the
antigen recognition process, helper T cells release
interleukin-2 (IL-2) in order to activate the proliferation
and clonal diversification of T cell subpopulations (Smith et
al., 1980). The proportion of cytotoxic T cells, helper T
cells and suppressor T cells is mainly determined by the
antigen presented. Many lymphokines such as IL-2, macrophage-
activating factor (MAF) (Steeg et al., 1982 Svedersky et
al., 1984), gamma-interferon and B-cell growth factors (BCGF)
will be secreted by helper T cells to regulate and stimulate
those other immunological components.
In the anti-tumour mechanisms, the-functions of T-cell
population are often over-emphasised by the immune
surveillance theory (Lotzova, 1985 Den Otter, 1986).
However, T cells are not the only cell type in the
surveillance mechanism but other cell types, including
natural killer (NK) cells, macrophages and other killer cells
(Grossman et al., 1986) may also play a role. Of course,
anti-tumour functions of T-lymphocytes are still observed in
different reports. The immunological rejection of solid
tumours (e.g. carcinomas and sarcomas) is independent of
antibody-mediated effector arms. From the experiments with T-
cell-depleted animals, tumour rejection responses cannot be
induced (Hellstrom and Hellstrom, 1974). Moreover, mice with
suppressed antibody-production due to the neonatal treatment
with anti-IgM antisera reject the MCA-induced tumours as
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effective as normal mice (Brodt and Gordon, 1978). In the
immunity-transfer experiments, T cells with helper cell
surface markers are found to be the major cells that induce
the anti-tumour activity in both rat (Fernandez-Cruz et al.,
1980 1982) and mouse (Bhan et al., 1981 Nelson et al.,
1981) tumour systems. Furthermore, B lymphoma target cells
can also be lysed by cloned or freshly prepared helper T
lymphocytes. The function(s) of these T cells is still
unknown. They may act as helper cells in a cytotoxic T
lymphocyte (CTL) response they may initiate a DTH response
or secrete lymphotoxin(s) or even activate other killer cells
to destroy tumour cells (Britten et al., 1984). From the data
accumulated so far, the anti-tumour activity of helper T
cells are mostly observed in mouse sarcomas (Fernandez-Cruz
et al., 1980 Perry and Greene, 1981 Forni and Giovarelli,
1984), leukaemias (Greenberg et al., 1985), hepatoma and
plasmacytoma (Fujiwara et al., 1984) and also in virus-
induced and chemically-induced rat tumours (Fernandaz-Cruz et
al., 1980).
In general, one of the important functions of helper T
cells is the production of inter,leukin-2 and the level of
IL-2 is suggested to be the determining factor of the outcome
of antigen recognition process- either non'-responsive or
positive. Moreover, the administration of anti-CD4 antibody
in vivo also suppresses the production of antibodies
(Benjamin and Waldmann, 1986). Beside IL-2 production, helper
T cells are also known to trigger the production of
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lymphokines by other cells, to activate the CTL responses
(Falk et al., 1983) and also to modify the functions of other
T cells. For example, in some non-immunogenic spontaneous rat
tumours, CTL precursor cells are inactive unless co-exist
with helper T cells. Furthermore, with the provision of
helper determinants in the form of the hapten trinitrophenol-
(TNP-) coupled tumour cells, CTL are generated and can be-
detected in vitro and also able to induce tumour graft
rejection in vivo (Zoller, 1985).
In brief, the T-cell defence system in -anti-tumour
mechanism deals mainly with virus-induced tumours. It may be
due to the major T lymphocyte function in protecting host
against virus infection because of the co-existence of viral
antigens on the tumour surface (Moller and Moller, 1978). The
role of T lymphocytes in both chemically-induced and
spontaneous tumours is not conclusive or minimal.
(II) MACROPHAGES
Macrophages together with polymorphonuclear leukocytes
constitute the first line of defence of the body against most
infections. Macrophages contribute at several stages in the
specific immunity leading to antibody production and cell-
mediated immunity directed against specific antigens.
Moreover, macrophages also exert a non-specific anti-
bacterial action with the co-operation of non-specific
opsonins and recognition factors. Many important biological
macromolecules such as components of complements,
transferrin, interferon, arginase and hydrolytic enzymes such
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as lysozyme and collagenase are secreted massively by
macrophages. Moreover, macrophages also scavenge tissue
debris, detoxify certain chemical substances and also
participate in the metabolism and disposition of iron, lipids
and proteins (Neveu, 1986).
In anti-tumour mechanisms, the macrophages play
important roles in both the afferent and efferent arms of the
immune system. Antigens such as TSTA are presented to T-
lymphocytes through macrophages (Askonas and Roelants, 1974).
In the anti-tumour mechanism, macrophages lyse the tumours
through the direct cytotoxic effect (macrophage-mediated
tumour cytolysis, MTC) or the antibody-dependent cellular
cytotoxicity (ADCC). In the MTC process, the cytolysis
involves two major steps. Initially, the macrophages must
bind to the tumour targets specifically through specific
receptor binding. After the binding, the macrophages will be
activated and secrete large amount of various cytolytic
mediators including cytolytic protease (CP)1arginase,
thymidine, tumour necrosis factor (TNF), interferon and
hydrogen peroxide (H202) etc.. Among these mediators, CP.is
claimed to be the major mediator in the MTC system (Adams and
Nathan, 1983 Johnson et al., 1984 Espevik et al., 1986). In
ADCC system, hydrogen peroxide is reported to be the major
cytolytic agent. However, even though these two mediators, CP
and H202, are suggested to be the major mediators inducing
cytolysis, the role of other mediators released by
macrophages should not be neglected. In fact, all mediators
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may participate in the cytolytic process and the co-operation
of them may induce a synergistic effect.
Macrophages can also be activated non-specifically by
the exposure to endotoxin, lipid A or double-stranded RNA,
after which the macrophages can inhibit the growth of
lymphoma and sarcoma cells in vitro. Some malignant targets
are lysed rapidly after exposure to activated macrophages.
The lysis is firstly due to cytostasis and then followed by
cell lysis a day later. Many investigations showed that
direct contact between activated macrophage and the target
cell is responsible for irreversible damages (Cleveland et
al., 1974 Kaplan et al., 1974). Exocytosis of lysozymes has
been proposed as the lethal step (Hibbs, 1974) and an enzyme
named arginase (Currie, 1978) is suggested to be the
responsible cytotoxic agent.
Many experimental tumours have been shown to contain
large amount of macrophages (Evans, 1972). In rat sarcoma,
macrophage content ranges from 3- 58% (Eccles and
Alexander, 1974). The macrophages in the tumour site were
shown to be of host origin and to enter the tumour presumably
as monocytes, as part of the immune responses to tumour
antigens. The relationship between macrophages in tumour site
and the growth and metastasis of tumour is still unknown
(Mantovani et al., 1986 McBride, 1986 Milas et al., 1987).
Even though some experiments indicated an inverse correlation
between the number of macrophages in tumour site and the
metastatic ability (Gauci et al., 1975 Fidler, 1985), other
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results showed a stimulating effect of intratumour
macrophages on tumour growth both in vivo and in. vitro
(Evans, 1972). Actually, the growing tumour was shown to
decrease the chemotactic activity of macrophages and also
impair their ability to reach inflammatory sites (Normann,
1978). Moreover, macrophages were also shown to mediate the
immu-nosuppression of host lymphocytes. The immunosuppressive
activity may limit the anti-tumour activities and enhance
tumour growth.
(III) NATURAL KILLER (NK) CELLS
Natural killer cells represent a heterogeneous
population of lymphoid cells that generate spontaneous
cytotoxic activity against tumour cells as well as virus-
infected cells in vitro (Kiessling and Wigzell, 1979). The
cytotoxicity of NK cells is non-specific and most effective
in eliminating lymphoid and myeloid tumours. For
fibrosarcomas, carcinomas and melanomas, the in vivo and in
vitro high cytotoxicity of NK cells is known. NK cells are
different from other immune cells by their morphology,
surface phenotype, antigenic markers and target cell
specificity. In human system, NK activity is mediated by
large granular lymphocytes (LGL) that is presented in about 5
- 10% of peripheral blood mononuclear cells (Saksela et al.,
1979 Timonen et al., 1981). Natural killer cells also
express few common surface markers as macrophages and also
several T-cell-associated markers. Moreover, they also
respond to T-cell mitogens and IL-2 because of the presence
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of IL-2 receptors on their plasma membrane.- NK cells
originate in the bone marrow and exhibit a' characteristic
organ distribution. The activity declines from peripheral
blood, spleen, lymph nodes and bone marrow and does not exist
in thymus (Herberman et al., 1975 Kiessling et al., 1975).
Moreover, NK activity is age-dependent as it is low during
the first 3 weeks, peaks at 6- 10 week old, and gradually
declines thereafter.
The anti-tumour activity of NK cells is observed in vivo
with transplantable tumours. Nude mice with high levels of NK
activity exhibited marked resistance against growth of
transplantable syngeneic, allogeneic and even xenogeneic
lymphomas and leukaemia (Warner et al., 1977 Minato et al.,
1979). In contrast, NK-resistant tumours grow equally well in
both nude and normal syngeneic mice. Xenogeneic cell lines,
when infected with RNA viruses, failed to form tumours when
transplanted into nude mice (Minato et al., 1979). This
rejection of virus-infected cells transplanted into nude mice
could be overcome by anti-interferon antibody treatment which
is known to inhibit the NK cell activation in vivo. Moreover,
depletion of-NK cells in vivo by treatment with anti-asialo-
GM1 antibodi-es increase the tumourigenicity and
transplantation percentage of NK-sensitive tumour cells
transplanted into syngeneic and nude mice (Barlozzari et al.,
1983) but have no effect on NK-resistant tumour cells.
Further supports also come from the studies with T-cell-
deficient chimeras which support the protective role of NK
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cells against tumour progression. Kassai et al. (1979) also
demonstrated that positively selected NK cells, when mixed
with NK-sensitive lymphoma cells and injected locally into
syngeneic mice, inhibited tumour growth. From these
observations, it is clear that both tumour cell sensitivity
to NK cell-mediated killing and the level of NK cell activity
in the host influence tumour growth in vivo. However, since
NK cells can only eliminate a small number of tumour
inoculated, they only serve as a rapidly-acting first-line
defence mechanism which is mainly effective during the early
phase of tumour implantation (Hanna and Filder, 1980). It may
be due to the inaccessibility of the tumour to NK cells,
inactivation of the intratumoural NK cells, excessive tumour
burden and the development of NK resistance during in vivo
growth. The low levels of infiltrating NK cells present
within the primary neoplasm and the resistance of fresh
tumour cells to NK cell-mediated cytotoxicity render it
unlikely that these cells play a significant role in
controlling the growth of established neoplasms. From some
investigations, it is claimed that the interferon-activated
NK cells can lyse human leukaemias, myelomas and solid
tumours significantly (Pattengale et al., 1982). Moreover,
rapid destruction of circulating tumour cells (Riccardi et
al., 1979 Hanna and Filder, 1980) by NK cells indicates that
NK may be an effective defence mechanism against hematogenous
tumour dissemination and metastasis.
Investigations on the killing mechanism of NK cells have
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shown that they can function as K cells in ADCC (Herberman
and Holden, 1978) in both mice and other species. The target
recognition process of NK cells is still unknown. However, it
may be related to (1) the specific interacting molecules on
both effector and target cells (Roder et al., 1979) (2) the
diffuse properties of target cell membranes (Moore, 1985) and
(3) the lack of MHC antigens (which are served as self-
recognition markers) on targets. Binding to a variety of NK-
sensitive and insensitive targets stimulates NK cells to
release substances named as NK cytotoxic factors (NKCF) which
may kill sensitive targets selectively (Wright and Bonavida,
1984). However, the nature of NKCF is still unknown.
(IV) SUPPRESSOR CELLS
Although being able to prevent tumour growth and
metastasis, cell-mediated immunity is also found to enhance
tumour growth. The specific and non-specific suppressor cells
present in hosts may shift the balance in favour of the
tumour and cause immunosuppression in host system (Ershler,
1986). Macrophages, 'T-lymphocytes and B-lymphocytes all
participated in the immunosuppressive mechanism. In many
chemically-induced, virus-induced and spontaneous tumour
systems, suppressor macrophages were found and exhibited
inhibition towards the functions of lymphocytes. Macrophages
are actively involved in the induction and maintenance of a
hyporesponsive state during tumour development (Siegel,
1985). The existence of suppressor T lymphocytes are also
reported (Baker, 1986 Ho et al., 1986 Mukherji et al.,
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1986 Prehn and Prehn, 1987). The suppressor T cells are
capable of inhibiting cytotoxic activity of T cells-and also
other lymphocytes against the tumours in mice (Eberlein et
al., 1982a North, 1982 North, 1986) and rats (Fernandaz-
Cruz et al., 1982 North, 1986). The end result of the
suppressor cell activity is to control the generation of CTL
responses. The actual target cell of them may be CTL itself
or helper T cell (North, 1985) and still open for discussion.
B-lymphocytes also caused suppression in tumour-bearing hosts
through the production of antibodies which will be discussed
in the next section.
1.3.2. HUMORAL IMMUNITY
From the above discussion, it is clear that the cell-
mediated immunity plays a role. in both directions, i.e.,
enhancement and inhibition of tumour growth, and thus it is
difficult for scientists to interpret the collected results.
With no exception, another branch of the immune system,
humoral immunity, also plays these dual roles.
The anti-tumour mechanisms mediated by humoral immunity
include antibody-mediated cellular cytotoxicity and
complement-mediated lysis of tumour cells. For ADCC, as
mentioned above, both macrophages and natural killer cells
are capable of mediating ADCC with their Fc receptors and the
antibody. Complement-mediated lysis of tumours is mainly
mediated by the natural antibody and complements and it may
be one portion of the natural immune surveillance mechanism.
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It was supported by the positive correlation between the IgM
level and duration of tumour burden (Greenberg and' Greene,
1976). However, the function of this complement-mediated
lysis in solid tumours in vivo is limited because of the low
penetrating ability of IgM.
In addition to the cytotoxic ability, antibodies also
enhance tumour growth. In the plasma of tumour-bearing hosts--,
various immunosuppressive agents have been identified. Among
them, the antibody, antigen and antigen-antibody complexes
are known. to play active roles. Moreover, the antigen-
antibody complexes have been suspected of having an active
role in the induction and maintenance of tolerance. The
functions of circulating immune complex (CIC) may involve:
(1) the binding of Fc receptors on the target cells and
masking their antigenic sites (2) reacting with the
lymphocytes and abrogating their reactivity against the
tumours (3) activating the suppressor cells (Gershon et al.,
1974) and (4) inhibiting the activity of effector cells such
as natural killer cells (Oldstone and Moretta, 1977). Some
investigations also show that the CIC may cause the decline
of interleukin production in hosts (Ravikumar et al., 1984).
1.4. IMMUNOTHERAPY
The study of tumour immunology not only helps to clarify
the immunological changes in tumour-bearing host but also
provides an approach for the treatment of cancer patients.
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To cure the tumour host through its own immune system
is known as immunotherapy. Immunotherapy is classified into
two major categories: active and passive one.- Active
immunotherapy is based on the assumption that a growing
tumour does not induce the maximal immune response in the
host. The purpose of active immunotherapy is to immunize the
host with agents that can elicit the host's immune responses
against tumours. Immunizing the host with tumour-specific
antigens is known as active specific immunotherapy. Using
non-specific immune stimulants, such as BCG and
Corynebacterium parvum, to activate the immune, system is
called active non-specific immunotherapy. Since the turn of
the century, many attempts have been made to induce specific
immunity in cancer patients by immunization with tumours.
Some well-documented evidence suggested that immunity of
animal and human hosts can be enhanced by active
immunization. Recently, the use of whole tumour cell vaccine
or vaccine consisting of subcellular components are the
common approaches of the active immunotherapy used in man and
animals. Besides these approaches, the combination of
specific and non-specific immunotherapy is also another
possible route. The effectiveness of active immunotherapy in
clinical applications is still not determined and, perhaps,
will take a long time to become successful (Morton, 1986).
Passive immunotherapy involves the transfer of previously
sensitized immunologic agents, including immune cells and
sera. Mainly, adoptive transfer refers to the transfer of
cells, such as lymphocytes, macrophages or natural killer
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cells. Several workers induced regression of both
autochtonous and transplanted tumours in animals. by the
administration of a large number of immunized cells (Fefer,
1969). Berendt et al. (1980), on the other hand, induced a
complete regression of murine Meth A fibrosarcoma by
intravenous (i.v.) infusion of sensitized T cells from immune
donors. Other workers also found similar results (Cheever et
al., 1981 Eberlein et al., 1982b). In human, the blood
lymphoid cells isolated from cancer patients were
successfully expanded 10,000 fold in vitro in the presence of
IL-2. In addition, -IL-2 can also induce the generation of
both natural killer cells and lymphokine-activated killer
(LAK) cells (Grimm et al., 1983) which are capable of killing
NK-resistant targets. Nevertheless, the usefulness of
adoptive transfer in clinical cases has yet to be determined.
Since the immunosuppressive factors present in the host
can limit the immunological functions of the host, scientists
have tried to remove these circulating immunocomplexes as
well as IgG by plasma absorption with Staphylococcus aureus
containing Protein A and some preliminary results were
reported (Ray et al.*, 1982). From the recent studies, tumour
regression is mainly due to the presence of the staphyococcal
agents, protein A, enterotoxin, and other factors. The use of
plasma absorption in clinical treatment of cancers is still
under active investigation.
In conclusion, tumour immunology is by no mean simple
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and the therapeutic methods based on the tumour immunology
may be too hasty and still premature. Further studies in the
clinical applications are required.
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I. M A T E R I A L S
Animals
Inbred BALB/c (H-2d), C57BL/6J (H-2 b), outbred I.CR mice,
Lewis rat and guinea pigs were bred at the University Animal
House, The Chinese University of Hong Kong. In each
experiment, animals of the same age (6- 8 week old) and sex
were used.
Calf Serum (CS)
Calf serum obtained from Gibco, U.S.A. was stored
at -20 °C as 10 and 20 ml aliquots. Heat-inactivated calf
serum (HICS) was prepared by incubating the aliquots at
16 °C for 30 minutes (mins).
Cell Lines
Several murine cell lines including EL-4(H-2b),
MBL-2 (H-2b), P815-X2 (H-2d) and YAC-1 (H-2a) were used in
this study. All these cell lines were maintained mainly
in suspension culture in RPMI medium supplemented
with 10% foetal calf serum (FCS) and containing antibiotics
(100 units/ml of penicillin G, 100 pg/ml of streptomycin
sulfate and 3 µg/ml of fungizone).
EL-4 was obtained from the Department of Parasitology,
National Institute for Medical Research, London. It is a
benzopyrene-induced T cell lymphoma of C57BL/6J mice and was
used for the large scale production of interleukin-2 in
vitro.
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MBL-2 tumour is a Moloney leukemia virus-induced T-cell
lymphoma of C57BL/6J mice and was the major tumour model
used. It was maintained in vitro in suspension culture and in
vivo by weekly intraperitoneal (i.p.) passage in syngeneic
mice.
P815-X2 is a methylcholantrene-induced mastocytoma of
DBA/2 mice and was used as target cell in cytotoxic T cell
assay. YAC-1 is a Moloney virus-induced T-cell lymphoma of
A/Sn mice and was used as target cell in natural killer cell
assay.
Complement (C')
Guinea pig serum provides a source of complement. Blood
of anaesthetized guinea pig was collected by cardiac puncture
with a 10 ml syringe fitted with a 19G needle. Whole blood
was immediately allowed to clot by standing at 4 °C for
3 hrs. Clear serum was collected without disturbing the clot.
The serum was freed of red cells and debris by
centrifugation. In order to remove the autoantibodies
against sheep red blood cells (SRBC) in serum, the serum was
incubated with excess S-RBC at 4 °C for 30 mins. After removal
of SRBC by centrifugation, the serum was stored at -20 °C
as 1 ml aliquots. Complement activity was tested before use
A I mPn c_in
Corynebacterium parvum (C. parvum)
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Formalin-killed Corynebacterium parvum was obtained from
Wellcome Research Lab., U.K. as 7 mg/ml and. kept at 4 °C and
made to the appropriate concentrations with phosphate-
buffered-saline (PBS) for injection.
Ficoll-Isopaque Solution
Ficoll 400 was purchased from Pharmacia Fine Chemicals,
Sweden and metrizoic acid was obtained from Sigma Chem. Co.,
U.S.A.. 14 g of Ficoll 400 was dissolved in 100 ml DDW (14%,
w/v) and stirred overnight. Ficoll solution was autoclaved
and kept at 4 °C. 30 ml of metrizoic acid was mixed
with 70 ml of Ficoll 400 solution and the mixture was
protected from light by wrapping the bottle with tin foil.
This solution was stored at 4°C and warmed up to room
temperature before use.
Cyclophosphamide (CY)
Cyclophosphamide was obtained from Sigma Chem. Co.,
U.S.A.. Stock. solution was prepared as 10 mg/ml with normal
saline and stored at -20 °C before use.
Foetal Calf Serum (FCS)
Foetal calf serum was obtained from Gibco, U.S.A. and
was stored as 10 and 20 ml aliquots at -20 °C until use.
Heat inactivated FCS (HIFCS) was prepared by incubating the
aliquots at 56 °C for 30 mins. FCS was usually used as a
supplement to RPMI medium for cell culture and the final
concentration was normally 10%.
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Gossypol
Gossypol was purchased from Sigma Chem.- Co. -U.S.A..
Stock solution was prepared as 1 mg/ml in absolute ethanol
and stored as 0.1 ml aliquots at -20 °C.
Latex Particles
1% (w/v) latex (0.8 µm, Sigma Chem. Co., U.S.A.) in PBS
was kept at 4.°C. The latex suspension was sonicated'for
10 mins to break the aggregates before use.
2-Mercaptoethanol Solution (2-ME)
A 0.1 M stock solution of 2-mercaptoethanol (Sigma Chem.
Co., U.S.A.) was prepared with sterilized plain RPMI medium
and kept at -20 °C in 0.5 ml aliquots.
Mitogens
Mitogens used in the in vitro culture include
concanavalin A (Con A), phytohaemagglutinin (PHA),
lipopolys.accharide (LPS) and dextran sulfate (DS). They were
obtained from the Sigma Chem. Co., U.'S.A.. Stock
solutions (1- mg/ml) in PBS were sterilized by millipore
filtration and kept as 0.5 ml aliquots at -20 °C.
Mitomycin C Solution
Mitomycin'C (from Streptomyces caespitosus, Sigma Chem.
Co., U.S.A.) was dissolved in sterile PBS with a final
concentration of 0.5 mg/ml. It was protected from light by
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wrapping the vial with tin foil and stored at 4 °C.
Penicillin-Streptomycin-Fungizone Solution (PSF)
Penicillin-streptomycin-fungizone solution was purchased
from Gibco, U.S.A. and contained 10,000 units/ml of
penicillin G, 10,000 pg/ml of streptomycin sulfate and
300 µg/ml of amphotericin B. This stock solution was stored
at -20 °C in 5 ml aliquots. Generally, complete RPMI culture
medium was supplemented with 10% FCS and 1% PSF.
Phosphate-buffered-saline (PBS)
PBS was prepared by dissolving 8.0 g NaCl, 0.2 g KC1,
1.15 g Na2HPO4 and 0.2 g KH2PO4 in 1000 ml double-distilled
water (DDW). The pH of the solution was adjusted to 7.2- 7.4
and the solution was sterilized by autoclaving at 121 °C for
15 mins.
Picolinic Acid (PA)
Picolinic acid (5 mg/ml) was freshly prepared in PBS
just before use. The dose used was 0.5 ml for each C57BL/6J
mouse with a body weight of 25 g.
Poly I:C
Poly I:C purchased from Sigma Chem. Co., U.S.A. was
dissolved in PBS as 1 mg/ml and kept at 4 °C. Each mouse




RPMI-1640 powder (Sigma Chem. Co., U.S.A.)'for 1 litre
preparation was dissolved in 1 litre of DDW and supplemented
with 0.85 g of NaHCO3 and 4.766 g Hepes (Sigma Chem. Co.,
U.S.A.). The medium was adjusted to pH 7.2- 7.4 and
sterilized by membrane filtration.
Scintillant
Scintillant was prepared by mixing 0.01% (w/v)
dimethyl-1,4-bis (2-(5-phenyloxazol)) benzene (POPOP) and
0.4% (w/v) 2,5-diphenyloxazole (PPO) in Toluene (Fisher) and
wastirred overnight before use.
Sheep Erythrocytes (SRBC)
Sheep erythrocytes purchased from Serotec. Co., U.K.
were washed three times with PBS before use. SRBC were
aliquoted and stored at 4 °C. Generally, each batch was used
within 2 months.
Silica
Silica was suspended in PBS (10 mg/ml) and sonicated for
5 mins before use. The dose used was 0.2 ml (2 mg/mouse) i.v.
for each mouse.
Na 51 CrO4 Solution
Na 51 CrO4 solution (350- 600 mCi/mg Chromium) wa:
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purchased from Amersham, U.K.. Working solution was diluted
to about 4 mCi/ml with sterilized RPMI supplemented' with lx
antibiotics. For maximum labelling, 200 µCi 51Cr was added
to 5 x 106 cells in 0.1- 0.5 ml volume and incubated
at 37 °C for 1 hr with occassional gentle shaking.
Thioglycollate Solution
10% thioglycollate broth was prepared by
dissolving 100 g dehydrated thioglycollate powder (Difco) in
1 litre of cold DDW and heated to boiling to dissolve the
powder completely. Solution was aliquoted into 20 ml bottles
and autoclaved (15 lb/in, 121 °C, for 15 mins). The broth
was protected from light by wrapping with tin foil and kept
at room temperature for at least a month before use.
3H-Thymidine Solution (3H-TdR)
3H-thymidine (2 Ci/mmol) was purchased from Amersham
Co., U.K.. 0.5 µCi/ pl working solution was prepared by
diluting the stock solution with sterilized PBS. For pulse
labelling, 1 µl working solution was added to each culture
Trypan Blue Solution
0.1% (w/v) Trypan blue (Sigma Chem. Co., U.S.A.) in PBS
was used to assess the viability of cells.
well.
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II. M E T H 0 D S
Cell Preparation and Isolation:
Peritoneal Exudate Cells (PEC)
Mice were killed by excessive exposure to anaesthetic
ether. The skin at the abdominal area was cleaned with 70%
ethanol. The skin of the abdomen was cut and pulled
apart. 5 ml of ice-cold PBS were injected i.p.. Peritoneal
fluid was collected by using a 5 ml syringe fitted with a 19-
gauge needle. Mice were lavaged three times. The cells were
pelleted by spinning at 250x g for 5 mins at 4 °C and washed
with cold PBS twice before use.
Spleen Cells
Spleens from groups of 3 to 4 mice were removed
aseptically, minced with a pair of scissors and pressed
through a sterilized 60 mesh stainless steel screen with the
plunger of a plastic 5 ml syringe. Large cell clumps and
debris were removed by centrifuging at 300x g for 5 seconds.
The cell suspension was then spun at 300x g and washed twice
with plain RPMI medium. Single cells were resuspended in
complete RPMI medium and kept at 4 °C. Viability of the cell
suspension was determined by the trypan blue dye exclusion




PEC or splenocytes were adjusted to 10 /ml in complete
RPMI medium and 200 µl of the cell suspension was added
into each well of a flat-bottomed 96-well microtiter plate
(Flow Lab. Ltd., U.K.). The plate was incubated
for 3- 4 hrs at 37 °C in a humidified atmosphere
containing 5% CO2 in air. Due. to the adherence property of
macrophages, they will be attached firmly onto the plastic
surface. In order to remove the non-adherent cells, the
supernatant was discarded and the plate was washed with warm
RPMI medium three times.
Mitomycin C Treatment of Cells
Splenocytes or tumour cells were adjusted to
1- 6 x 107 /ml in complete RPMI medium and 50 pl of
mitomycin C solution (0.5 mg/ml) was added to each ml of cell
suspension. The mixture was incubated for 30 mins at 37 °C
with occassional shaking. Cells were washed for three times
before use.
Ficoll-Isopaque Separation
Cell suspension and Ficoll-Isopaque solution were
prewarmed to room temperature in water bath. 4 ml of Ficoll-
Isopaque solution was added to a polycarbonate tube and 2- 6
ml of the cell suspension was gently layered on top of the
Ficoll-Isopaque solution. The tube was centrifuged at 2000x g
for 20 mins. Viable cells were collected by harvesting the
interphase cell layer. The cell were washed with RPMI medium
three times before use.
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Lymphocyte Cultures:
In Vitro Lymphocyte Transformation
The blastogenic responses of lymphocytes to the T-cell
mitogens Con A, PHA and the B-cell mitogens LPS, DS were
determined by the measurement of the rate of DNA synthesis by
the incorporation of 3H-thymidine into DNA. Viable
splenocytes (5 x 105 cells/well) were cultured with
different mitogens in 0.2 ml complete RPMI medium'in flat-
bottomed 96-well microtiter plates. Optimal concentrations of
mitogens used were 4 pg/ml for Con A, 10 µg/ml for
PHA, 30 pg/ml for LPS and 40 pg/ml for DS. The cultures
were incubated for 48 hrs at 37 °C in a humidified atmosphere
containing 5% CO2 in air and pulsed with 0.5 pCi 3H-TdR
for 6 hrs before harvesting onto glass fibre filter using
Titertek multiharvester (Flow Lab. Ltd., U.K.). Incorporated
3H-TdR label was counted in a Beckman scintillation counter
(Beckman LS1801, U.S.A.) and results were expressed as





Blank: net cpm of medium only
Control: net cpm of cell only
Test: net cpm of culture with mitogens
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Suppressor Cell Assay
Splenocytes from tumour-bearing mice (TBM) and normal
mice (NM) were adjusted to 5 x 106 /ml in RPMI medium
supplemented with 10% FCS. Various TBM/ NM ratios were
adjusted by mixing the two cell populations. The suppressor
cell activity was tested by lymphocyte transformation assay
with mitogens Con A and LPS. By comparing the stimulation
index of individual culture, the suppressor cell activity in
the splenocyte populations could be estimated.
Generation of Alloreactive Cytotoxic T Lymphocytes'(CTL)
Alloreactive CTL were generated as described by Engers
et al., (1976). Briefly, 2 x 105 mitomycin C-treated BALB/c
splenocytes were co-cultured with 105 C57BL/6J splenocytes
in 0.2 ml RPMI medium supplemented with 10% HIFCS and
5 x 105 M 2-ME in round-bottomed 96-well microtiter plate
(Costar, Cambridge, U.S.A.). The culture was incubated
at 37 °C under a gas phase of 5% CO2 in air. Each well was
replenished on day 2 and day 5 with 50 pl R-PMI medium
supplemented with 10*% HIFCS and 5 x 10-5 M 2-ME.
Cytotoxicity of the effector cells generated was measured on
day 6, using the standard 51Cr-release assay.
Assay of Cell-Mediated Lympholysis
For the measurement of cell-mediated
lympholysis, 5 x 106 P815 target cells were labelled with
200 µCi Na51Cr04 for 1 hr at 37 °C with occassional gentle
shaking. The cells were then washed twice with RPMI medium
37
and cell concentration was adjusted to 105 /ml in RPMI medium
supplemented with 10% HIFCS. On day 6, 0.1 ml supernatant
was removed from each well of the primary culture and
104 51Cr-labelled P815 cells in 0.1 ml volume were added.
After a further incubation period of 8 hrs, 0.1 ml
supernatant was carefully sucked up from each well and its
radioactivity was counted in a Beckman gamma counter. For
spontaneous lysis, 0.1 ml RPMI medium supplemented with 10%
HIFCS was added to 0.1 ml labelled target. For maximum
releasable 51Cr, 0.1 ml 10% triton-X100 was added to 0.1 ml






M: Maximum releasable counts
S Spontaneous rel-ease counts
T: Test culture counts
Mixed Lymphocyte Tumour Culture
Totally 1.2 x 108 C57BL/6J splenocytes were co-cultured
with 6 x 106 mitomycin C-treated MBL-2 tumour cells in'
50 ml RPMI medium supplemented with 10% FCS and 5 x 10_5 M
2-ME and incubated-at 37 °C in a humidified atmosphere of 5%
CO2 in air. After 6 day incubation, the cytotoxicity of the
effector cells generated was measured by the standard
51Cr-release assay using MBL-2, P815 and YAC-1 cells as
--, r.-. f a- r.
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Delayed Type Hypersensitivity (DTH)
The procedure described by Leung et al. (1986) was
essentially followed. C57BL/6J mice in groups of 6- 8 were
given an i.v. injection of 1 x 106 SRBC in 0.2 ml PBS for
sensitization. Control mice were injected i.v. with an equal
volume of PBS. Four days after antigen sensitization, the
left and right hind footpad thickness of mice were measured
using a Schnelltaster caliper (Kroplin, Germany) and their
mean footpad thickness determined. Each mouse was then
challenged with 108 SRBC in 50 pl of PBS, injected
subcutaneously (s.c.) into each right hind footpad. The same
volume of PBS was injected into the left hind footpad as
self-control. Footpad swelling was measured at 24, 48 and 72
hrs after the antigen challenge and results were expressed as
the percentage mean increase in footpad thickness (Leung et
al., 1980) which was calculated as follows:
Tr- T1
% mean increase in footpad thickness - x 100
Ta
where
Tr Thickness of right hind footpad
Tl Thickness of left hind footpad
Ta Mean thickness of left and right footpad
of all experimental animals before challenge
Humoral Antibody Response Against SRBC
Haemolytic Plaque Assay
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C57BL/6J mice in groups of four were immunized i.v.
with 4 x 108 SRBC. Splenocytes obtained four days later were
resuspended at 107 /ml in complete RPMI medium. SRBC (1.5-
2.0 x 109 /ml) were mixed with guinea pig complement in an
appropriate ratio. 175 µl of the SRBC-complement mixture was
then mixed with 75 µl splenocytes in the wells of a flat-
bottomed 96-well microtiter plate. An aliquot of 34 pl was
added to each microchamber formed by adhering two glass
slides with stripes of double-sided Scotch tape. The edges of
each microchamber were sealed with melted paraffin wax.
Microchambers containing the cell mixture were laid-flat and
incubated for 1 hr at 37 °C. IgM plaques were counted under
an inverted microscope. Results were the mean of duplicate
chambers and expressed as the number of plaque-forming cells
(PFC) per 106 splenocytes.
Haemagglutination Assay
C57BL/6J mice were immunized i.v. with 4 x 108 SRBC in
0.2 ml PBS. The sera of mice were collected on day 7, 14 and
21 after antigen injection. The immune sera were heat-
inactivated at 56 °C for 30 mins in order to remove non-
specific inhibitors. Serial 2-fold dilutions of the sera were
made with PBS in round-bottomed 96-well microtiter plates in
a final volume of 50 µl/well. 50 pl of 0.5% SRBC was added
to each well and the plates were kept at room temperature for
at least 1 hr and the haemagglutination endpoints were
recorded. The titre of each serum was expressed as the
reciprocal of the highest dilution of the serum that gave a
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positive result of haemagglutination.
In Vivo Migration of Macrophages
The method described by Gervais et al. (1984) was used.
C57BL/6J mice in groups of 4 were injected i.p. with
2 ml 10% Difco's thioglycollate broth. PEC of each mouse
were harvested and counted three days later. PEC of the same
group were pooled and adjusted to 2 x 106 cells/ml in
complete RPMI medium. 0.2 ml of pooled PEC suspension of each
group was then added into triplicate wells in a flat-bottomed
96-well microtiter plate. After at least 3 hrs of
incubation at 37 °C, the adherent cells were attached firmly
onto the wells. By counting the number of non-adherent cells,
the number of adherent cells could be deduced.
Phagocytosis Assay
The method of Kohl et al. (1977) was followed with minor
modifications. Briefly, PEC elicited with 2 ml thioglycollate
broth were harvested with PBS after 3 days and the total
number of PEC was counted. 2 x 106 PEC were then added to a
siliconized borosilicate test tube and pelleted by
centrifugation at 300x g for 5 mins. Cells were resuspended
in 0.5 ml complete RPMI medium and 25 µl of 1% latex
particles were added to each tube. The mixture was incubated
in a shaking waterbath at 37 °C for 1 hr. The unphagocytised
latex particles were removed from the mixture by layering the
cell-suspension onto 2 ml CS and then centrifuging at 300x g
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for 5 mins. The cell pellet was resuspended in 0.2 ml
complete RPMI medium and the phagocytic cells were counted
with trypan blue under a phase contrast microscope. Cells
containing at least three latex particles were considered as
phagocytic.
Macrophage-Mediated Cytostasis
Cytostatic PEC cells were obtained by in vivo activation
with picolinic acid (PA) (Ruffmann et al., 1984). C57BL/6J
mice were injected i.p. with PA at 100 mg/Kg body weight. PEC
were harvested three days later with cold PBS. After washing
three times with plain RPMI medium, the cells were
resuspended in complete RPMI medium at 2 x 106 /ml. 0.1 ml
PEC suspension was added into each well of a flat-bottomed
96-well microtiter plate and incubated at 37 °C for 6 hrs.
Non-adherent cells were removed by washing three times with
warm RPMI medium. 104 MBL-2 cells supplemented with 2 ng/ml
LPS were added to each well in a total volume of 0.2 ml.
After 48 hr incubation at 37 °C, each well was pulsed with
0.5 µCi 3H-TdR and then harvested 5 hrs later with a Titertek
multiharvester. The percentage growth inhibition of MBL-2
cells induced by the activated macrophages was calculated as
follows:
3H-TdR incorporation of MBL-2 cells
in the presence of macrophages
x 100Cytostasis= 1
3H-TdR incorporation of MBL-2 cells
in the absence of macrophages
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Natural Killer Cell Assay
C57BL/6J mice were injected i.v. with -100 pg poly I:C
(Sigma Chem. Co., U.S.A.) in 0.2 ml PBS. Mice were sacrificed
by cervical dislocation 24 hrs later. Different
concentrations of effector cells (0.1 ml) were added
onto a flat-bottomed 96-well microtiter plate and mixed
with 2 x 104 51Cr-labelled YAC-1 target cells (0.1 ml) so
that the effector-to-target cell ratios were 100: 1 and
50 1. After 4 hr incubation at 37 °C, 0.1 ml of
supernatant was sucked up and counted for radioactivity in a
mammaounter.
Production of Interleukin-2
(A) By Con A-activated Mouse Splenocytes
The method described by Leung et al. (1986) was modified
for interleukin-2 production. Briefly, 1 x 107 mouse
splenocytes in 1 ml complete RPMI medium were added onto the
wells of a Linbro 24-well plate (Flow Lab., U.K.) in the
presence of 5 fig/ml Con A. The culture was incubated
for 24 hrs in a humidified atmosphere containing 5% CO2 in
air at 37 °C. Supernatants were collected and 0.1 ml swelled
Sephadex G-100 (Pharmacia, Sweden) was added to each sample
to remove any residual Con A. After shaking for 3 hrs in a
shaker at room temperature or kept at 4 °C overnight,
Sephadex was removed by centrifugation and the supernatant
was sterilized by membrane filtration. The collected
supernatants contained a mixture of lymphokines
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including IL-2.
(B) By EL-4 Lymphoma
Large scale production of interleukin-2 was achieved by
in vitro stimulation of EL-4 cells with phorbol-myristate-
acetate (PMA) (Farrar et al., 1980). 4 x 107 EL-4 cells were
cultured with 4 µg PMA in 40 ml RPMI medium supplemented with
2% FCS and incubated at 37 °C in 5% CO2 for 6 hrs. After
two washings, the cells were resuspended in 40 ml RPMI medium
containing 5% FCS and incubated for a further period of 24
hrs. Cells were then pelleted by centrifugation at'300x g for
5 mins and the supernatant was harvested and stored at -20 °C
as 10 and 20 ml aliquots. IL-2 activity of the supernatant
was measured by using the IL-2 assay as described by Lafferty
et al. (1980).
Interleukin-2 Assay
IL-2 activity was measured by the maintenance assay as
described by Lafferty et al. (1980). In essence, Con A
blasts were prepared from a 3 day culture of 107 C57BL/6J
splenocytes in 10 ml RPMI medium supplemented with 10% FCS,
1 µg/ml Con'A and 5 x 10-5 2-ME in a 25 cm2 culture flask.
Con A blasts were washed three times with plain RPMI medium
to remove any residual Con A. Viable Con A blast cells were
resuspended at a concentration of 4 x 105 /ml. Meanwhile,
serial 2-fold dilutions of IL-2 samples were made in. 96-well
flat-bottomed microtiter plate in 50 Al final volume. 50 Al
of the blast cells were added to each well and the mixtures
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were incubated at 37 °C for 16- 24 hrs. The cultures were
pulsed with 0.5 pCi 3H-TdR and then harvested 5 hrs later
using a Titertek multiharvester. The radioactivity
incorporated was determined by counting in a Beckman liquid
scintillation counter.
Production of Tumour Necrosis Factor-Containing serum ('1'Nb)
TNS was a gift from Dr. K. P. Fung, Department of
Biochemistry, The Chinese University of Hong Kong. Briefly,
mice were injected i.p. with 1 mg formalin-killed C. parvum
in 0.5 ml saline. Seven days after injection, 25 pg LPS in
0.2 ml saline were administered i.v.. The mice were bled from
the subclavian vessels 90 mins later. Control sera were
obtained from C. parvum-injected mice challenged with 0.2 ml
saline or from mice treated with LPS only. Pooled sera were
incubated at 56 °C for 30 mins and were filter-sterilized and
stored -20 °C until use. TNF activity was assayed by the
method of Ha et al. (1985) and was found to a titer of 500.
Anti-tumour Activity of Various Drugs in vivo
C57BL/6J mice were injected i.p. with 2 x 105 viable
MBL-2 cells in 0.5 ml PBS. One day later, drugs were injected
daily intraperitoneally for 6 consecutive days and the
peritoneal tumour cells were harvested with a 5 ml syringe
fitted with a 19G needle 7 days post tumour challenge. Viable
tumour cells were counted using the trypan blue dye exclusion
method.
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Preparation of Various Antigens for In Vivo Injection
UV-irradiated, glutaraldehyde-treated and sonicated
tumour cells were used for in vivo injection. UV-irradiated
tumours cells were prepared by exposing tumour cells under
ultra-violet (UV) light. 2 x 107 /ml MBL-2 cells were placed
in 75 mm2 culture dish. The total volume should*be less than
5 ml so that they formed a monolayer. Then the culture dish
was exposed to a 25W germicidal UV lamp at a distance of 5 cm
for 5 mins. Tumour cells were harvested and washed twice with
PBS and then resuspended to 5 x 107 /ml. Viability was
checked before and after incubating the irradiated cells at
17 Or for 24 hrs.
Glutaraldehyde-treated tumour cells were prepared by
incubating 2 x 107 viable MBL-2 cells with 0.02%
glutaraldehyde (Sigma Chem. Co., U.S.A.) in 0.2 ml PBS
for 10 mins at room temperature. Cells were washed three
times by centrifugation at 300x g for 5 mins at 4 °C. Cells
7
were resuspended at 5 x 10 /ml in PBS for i.v. injection.
To prepare sonicated suspension of MBL-2
cells, 5 x 107 /ml viable tumour cells were washed three
times with sterilized PBS and resuspended in less than 5 ml
total volume. Cell suspension was sonicated at step 6 (Heat
Systems-Ultrasonics Inc., U.S.A.) for 1 minute at 4 °C.
Intact cells were checked with 0.1% trypan blue solution.
Protein concentration of sonicated tumour suspension was
determined by Folin-Lowry assay (Lowry et al., 1951).
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Statistical Analysis
All results were expressed as the arithmetic' mean+
standard error (S.E.). Student's t-test was used to determine
the confidence limits in group comparison. Normally, p 0.05
was regarded as significant difference.
CHAPTER THREE INDUCTION OF HOST IMMUNE RESPONSES TO
A SYNGENEIC MURINE TUMOUR
C 0 N T E N T S
RESULTS
Mean Survival Time (MST) of Tumour-Bearing Mice3.1.
Effect of Immunization with Mitomycin C-Treated3.2.
MBL-2 Cells on In Vivo Tumour Growth
Cytotoxicity. of Peritoneal Exudate Cells (PEC)3.3.
Induced by In Vivo Immunization with Mitomycin C-
Treated MBL-2 Cells
Effect of C. parvum-Activated Macrophages on MBL-23.4.
Tumour Growth In Vivo
Cytotoxicity of C. parvum-Activated Macrophages3.5.
Against MBL-2 Tumour In Vitro
Cytostaticity' of Picolinic Acid-Activated3.6.
Macrophages Against MBL-2 Tumour
Effect of Macrophage Depletion on the Proliferation3.7.
of MBL-2 Tumour In Vivo
Effect of Macrophage Depletion on Mean Survival3.8.
Time (MST) of Tumour-Bearing Host
Induction of Natural Killer Activity by Tumour3..9.
Antigens
Failure to Induce A Delayed Type Hypersensitivity3.10.
(DTH) Response by MBL-2 Tumour In Vivo
Generation of Cytotoxic Cells in Primary Mixed3.11.
Lymphocyte Tumour Culture (MTLC) In Vitro
Antigen Specificity of the Primary Effector Cells3.12.




I N T R 0 D U C T 1 0 N
There is currently much interest in the study of the
roles of immune mechanisms capable of eliminating malignant
cells. It has been well-documented that both non-specific and
specific immune responses are involved in the defence of host
against tumour growth and dissemination (Brodt, 1983 Urban
and Schreiber, 1984). The presence or absence of
immunogenicity of a tumour will determine its growth
pattern, metastasic ability and also the immune responses of
host induced by the tumour. Various experimental tumour
models have shown that immunization of animals with tumour or
tumour extracts can either be prophylactic (Pellis et al.,
1980), therapeutic (Kahan et al., 1980) or can confer
different degree of immunity against subsequent tumour
challenge (Inaba et al., 1983). In the host immune system,
many different cell types, such as T and B lymphocytes, NK
cells and macrophages were reported to play important roles
in immune surveillance in vivo (Lotozova, 1985 Den Otter,
1986) and may cause the destruction of tumours. However,
since cancer actually embodies many different diseases
(Balch, 1986) and each disease has its own etiology, pattern
of metastases and even therapeutic approaches, thus, the
relative importance and the precise role played by each cell
type in influencing tumour growth and development differ
widely, depending not only on the host's intrinsic factors
but also on the type of tumour. Experimental data so far
accumulated indicate that the involvement of the immune
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system in the host responses to tumours is rather
complicated, and the net effect is determined by a•number of
mechanisms that might either inhibit or stimulate tumour cell
growth.
The studies of a wide variety of animal tumours have
contributed significantly to our basic knowledge of tumour
immunology. Scientists investigating different murine tumour
models have been trying to accumulate more information to
explain the relationships between tumours and their hosts. In
the present study, a Moloney leukemia virus-induced syngeneic
transplantable T cell lymphoma of C57BL/6J mice, designated
as MBL-2 tumour, was chosen as the experimental tumour model
for investigation. In this chapter, the properties and
immunogenicity of this tumour will first be analyzed.. In
addition, the contribution and the relative importance of the
non-specific versus the specific cell-mediated immune
mechanisms in defence of mice against MBL-2 tumour will be
examined.
49
R E S U L T S
3.1. MEAN SURVIVAL TIME (MST) OF TUMOUR-BEARING MICE
In order to study the complex immune responses
induced by a tumour, the influence of the tumour dose
and the route of inoculation on the growth of tumour in
its syngeneic host were first investigated. C57BL/6J
mice in groups of 10 were either injected with a higher
dose (5 x 106 cells) or a lower dose (2 x 105 cells) of
MBL-2 tumour given intravenously (i.v.),
intraperitoneally (i.p.) and subcutaneously (s.c.).
Survival time of each individual mouse was monitored for
at least one month and the results were shown in Fig.
3.1.. It was found that the mean survival time (MST) of
mice challenged with 5 x 106 MBL-2 cells were
11.00± 0.00, 15.10+ 2.08 and 16.20+ 1.32 days for
i.v., i.p. and- S.C. groups, respectively. Similar
pattern of MST was observed when mice were challenged
with a lower dose of tumour (Fig. 3.2.). The shortest
MST was 14.60+ 0.84 days for the i.v. group, followed
by 17.90+ 1.73 days for the i.p. group and the longest
one was 21.40.+ 2.67 days for the S.C. group. Moreover,
gross pathological examination had shown that
irrespective of the route of inoculation, metastasis was
observed in mice injected with 5 x 106 MBL-2 cells but
not in those injected with 2 x 105 tumour cells seven
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Fig. 3.1. MEAN SURVIVAL TIME (MST) OF TUMOUR-BEARING HOSTS
C57BL/6J mice in groups of ten were inoculated with
5 x 106 MBL-2 cells intravenously(),
intraperitoneally (△) or subcutaneously (□). The
survival time of each individual mouse was recorded
and the mean survival time (MST) of each group was
represented as group mean+ S.E.. The MST of i.v.,
i.p. and s.c. groups were 11.00+ 0.00, 15.10+
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Fig. 3.2. MEAN SURVIVAL TIME OF TUMOUR-BEARING HOST
C57BL/6J mice in groups of ten were inoculated with
2 x 105 MBL-2 cells intravenously(),
intraperitoneally (▲) and subcutaneously (■). The
survival time of each individual mouse was recorded
and the mean survival time (MST) of each group was
represented as group mean+ S.E.. The MST of i.v.,
i.p. and s.c. groups were 14.60+ 0.84, 17.90+




mice were usually inoculated s.c. with 2 x 105 MBL-2
cells for the majority of the experiments reported in
this thesis.
3.2. EFFECT OF IMMUNIZATION WITH MITOMYCIN C-TREATED MBL-2
CELLS ON IN VIVO TUMOUR GROWTH
Immunogenicity of a tumour is one of the critical
factors to determine whether the host can generate
specific immunological responses to reject the tumour.
Thus, in this experiment, the immunogenicity of MBL-2
tumour was evaluated by immunizing normal mice with'107
mitomycin C (MMC)-treated MBL-2 cells once, twice or
thrice before i.p. challenge with 2 x 105 viable MBL-2
cells. Tumour growth was assessed 7 days later by
counting the number of viable MBL-2 cells recoverable
from the peritoneal cavity of mice. As shown in Table
3.1., mice immunized with MMC-treated MBL-2 cells once,
twice or thrice before tumour inoculation demonstrated a
significant suppressive effect on MBL-2 tumour growth in
vivo.
3.3. CYTOTOXICITY OF PERITONEAL EXUDATE CELLS (PEC) INDUCED BY
IN VIVO IMMUNIZATION WITH MMC-TREATED MBL-2 CELLS
To test the hypothesis that immunization with MMC-
treated tumour can activate tumouricidal cytotoxic
peritoneal exudate cells (PEC), normal mice were
immunized with 107 MMC-treated MBL-2 cells i.p. and PEC
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Table 3.1. EFFECT OF IMMUNIZATION WITH MITOMYCIN C-TREATED







aMice in test groups I, II and III were immunized with 10
mitomycin C-treated MBL-2 cells once, twice and thrice
respectively. Each immunization was done at least 20 days
after the last immunization. Mice were then inoculated with 2
x 105 MBL-2 cells i.p. and the tumour size was measured 7
days later.
bResults were expressed as mean tumour number+ S.E. for
groups of 6 mice.
Significantly different from the control unimmunized mice, p
0.01.
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were harvested 5 days afterwards. As it is known that
pretreatment of mice with cyclophospha-mide (CY) may
increase the ability of tumour cells to stimulate
specific effector cells involved in anti-tumour immunity
(Ophir et al., 1984), therefore another group of mice
was included which was pretreated with CY (100 mg/kg
body weight injected i.p.) two days before the
immunization. Cytotoxicity of the effector PEC against
MBL-2 target was measured by a 12 hr 51Cr-release assay
with effector-to-target (E/T) ratios of 50: 1 and 100:
1. Table 3.2. demonstrated that cytotoxicity of PEC
against MBL-2 target was observed in mice immunized with
MMC-treated MBL-2 cells but not in unimmunized mice. The
pretreatment with CY only slightly enhanced the
cytotoxicity of the induced PEC against MBL-2 cells in
the group immunized with MMC-treated MBL-2 cells but not
in the unimmunized group,
3.4. EFFECT OF C. PARVUM-ACTIVATED MACROPHAGES ON MBL-2 TUMOUR
GROWTH IN VIVO
The'results of the above experiments clearly showed
that immunization with MMC-treated tumour afforded
significant protection against inoculation with a
tumourigenic dose of MBL-2 cells and protection may be
mediated, at least in parts, by the activation of
tumouricidal cytotoxic PEC or macrophages. Thus, it is
of interest and importance to examine the role of
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Table 3.2. INDUCTION OF CYTOTOXIC PEC BY IN VIVO
IMMUNIZATION WITH MITOMYCIN C-TREATED MBL-2 CELLS







25.99+ 1.4112.64+ 1.73'C YT
aMice in groups of three were pretreated with PBS (Control
T groups) or 100 mg/kg cyclophosphamide (CY CYT groups)
two days before i.p. injection with 107 mitomycin C-treated
MBL-2 cells (T CYT groups) or PBS (Control CY groups).
After five days, PEC harvested were tested for their in vitro
cytotoxicity against 51Cr-labelled MBL-2 target in a 12 hr
51Cr release assay.
b.CStatistically different from their corresponding control (p
0.01).
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macrophages in restricting MBL-2 tumour growth in its
syngeneic host. Anti-tumour activity ofmacrophages can
be evaluated by two approaches: one is to activate the
macrophages by chemical means while the other is to
deplete the macrophages so that if the tumour growth is
suppressed in activated group or enhanced in depleted
group, macrophages may then play a role in the anti-
tumour mechanisms. In the following experiments, these
two approaches will be adopted. In the first set of
experiments, C57BL/6J mice were either pretreated with
PBS or C. parvum (700 µg/mouse injected i.p.) 3 days
before i.p. injection with 2 x 105 MBL-2 cells. As shown
in Table 3.3., prior injection of mice with a macrophage
activating agent such as C. parvum significantly
suppressed MBL-2 tumour growth in vivo.
3.5. CYTOTOXICITY OF C. PARVUM-ACTIVATED MACROPHAGES AGAINST
MBL-2 TUMOUR IN VITRO
In order to demonstrate that in vivo pretreatment
with C. parvum indeed activates cytotoxic tumouricidal
macrophages, mice were pretreated with 700 pg C. parvum
and their PEC were tested for tumouricidal activity 4
days later. This was done by co-culturing the PEC with
51Cr-labelled MBL-2 at E/T ratios of 25: 1 and 50: 1
for 12 hrs and the results were shown in Table 3.4.. It
can be seen that the cytotoxicity of PEC against MBL-2
tumour was significantly greater in C. parvum-treated
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Table 3.3. EFFECT OF C. PARVUM-ACTIVATED MACROPHAGES ON





a Mice in groups of eight were pretreated with PBS in control
group or 700 µg C. parvum in test group (CP) three days
before the inoculation of 2 x 105 MBL-2 cells i.p.. Tumour
size was measured by counting the total number of viable
tumour cells recoverable from the peritoneal cavity of each
mouse 7 days post tumour challenge and the results were
expressed as mean+ S.E..
bSignificantly different from control group (p 0.005).
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Table 3.4. CYTOTOXICITY OF C. PARVUM-ACTIVATED MACROPHAGES
AGAINST MBL-2 TUMOUR IN VITRO






aMice in groups of three were injected i.p. with PBS in
control group or with 700 µg C. parvum in the CP group 4 days
before the cytotoxic assay.
bCytotoxic assay was carried out with 51Cr-labelled MBL-2
tumour cells at E/T ratios of 25: 1 and 50: 1.
c Significantly different from control group (p 0.005).
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group than that of the control group.
3.6. CYTOSTATICITY OF PICOLINIC ACID-ACTIVATED MACROPHAGES
AGAINST MBL-2 TUMOUR
Apart from exhibiting cytotoxic activity,
macrophages can also exert their tumouricidal effect by
inhibition of tumour cell growth. Previously, it has
been demonstrated that MBL-2 cells are sensitive to
macrophage-mediated cytolysis, it is of interest to know
whether this tumour is also susceptible to macrophage-
mediated cytostatic effect. Mice were first activated by
i.p. injection of picolinic acid (PA) (100 mg/kg). PEC
were harvested 3 days later and the adherence cells
were co-cultured with viable MBL-2 cells in 96-well
flat-bottomed microtiter plate at E/T ratios of 10: 1,
25: 1 and 50: 1 respectively. After 24 hr incubation,
cultures were pulsed with 0.5 µCi 3H-thymidine and the
cells were harvested 6 hrs later. It was found that in
vivo injection of mice with PA could. enhance the
cytostatic activity of their macrophages against MBL-2
growth in vitro (Table 3.5.).
3.7. EFFECT OF MACROPHAGE DEPLETION ON THE PROLIFERATION OF
MBL-2 TUMOUR IN VIVO
Besides enhancing the cytotoxic and cytostatic
60




50: 125: 110: 1
41.08+ 7.11 73.85+ 3.75 94.26+ 1.37CONTROL
57.34+ 5.82 99.93+ 0.01' 99.92..+ 0.02cPA
aMice in groups of three were pretreated with PBS in control
group or 100 mg/kg picolinic acid in PA group 3 days before
the cytostatic assay.
bPeritoneal exudated cells of each group were pooled and the
cytostatic assay with E/T ratios of 10: 1, 25: 1 and 50: 1
was carried out with viable MBL-2 cells. After co-culturing
for 24 hrs, the cells were then pulsed with 0.5 µCi
3H-thymidine and harvested 6 hrs later. The ability of the
macrophages in the PEC to inhibit the growth of MBL-2 cells
was determined by the 3H-thymidine incorporation of the MBL-2
cells in the presence or absence of macrophages and
expressed as % cytostatic activity.
Significantly different from control group (p <0.01).
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activities of macrophages, another approach to
investigate the role of macrophages in anti-tumour
immunity is to deplete macrophages from the mice by
chemical means and examine whether tumour growth is
enhanced. Table 3.6. demonstrated the effect of
macrophage depletion on MBL-2 tumour growth in vivo. In
order to eliminate the macrophages, 2 mg of silica was
injected i.v. to C57BL/6J mice 2 days before the i.p.
inoculation of 2 x 105 MBL-2 cells (Group II). Moreover,
to ensure the complete removal of macrophages, another
additional dose of silica was injected 2 days after
tumour challenge (Group III). As seen in Table 3.6.,
although the depletion of macrophages apparently caused
a slight enhancement (25- 30%) in the growth of MBL-2
tumour in vivo when compared to the control, however,
such a difference was turned out to be statistically
insignificant.
3.8. EFFECT OF MACROPHAGE DEPLETION ON MEAN SURVIVAL TIME
(MST) OF TUMOUR-BEARING HOST
The effects of macrophage depletion on the survival
rate and the survival time of tumour-bearing mice were
studied. C57BL/6J mice in groups of 11 were similarly
treated as described in section 3.7.. As shown in Fig.
3.3., no significant difference in the survival rate or
MST was observed between the untreated and the silica-
treated groups, indicating that macrophage depletion had
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Pable 3.6. EFFECT OF MACROPHAGE DEPLETION ON THE
PROLIFERATION OF MBL-2 TUMOUR IN VIVO
TUMOUR COUNTdSi.a MBL-2b Sic




a2 mg silica was injected i.v. on day -2.
b2x 105 MBL-2 cells were inoculated i.p. on day 0
2 ma silica was injected i.v. on day +2.
dNumber of tumour cells was measured 7 days after tumour
inoculation. Both control and silica-treated groups showed
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Fig. 3.3. EFFECT OF MACROPHAGE DEPLETION ON MEAN SURVIVAL
TIME (MST) OF TUMOUR-BEARING HOST
C57BL/6J mice in groups of eleven were injected
i.v. with one single injection of-2 mg silica 4
days before() or two i. v. injections of 2 mg
silica 2 days and 4 days before() the i.p.
inoculation of 2 x 105 MBL-2 tumour. Mice of the
control group() were inoculated i.p. with 2 x
105 MBL-2 cells only.
The MST among the three groups were not
significantly different (p >0.3) implicating
that the effect of macrophage depletion did not
affect long-term tumour proliferation in vivo.
% SURVIVING
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no long term effect on MBL-2 tumour growth in vivo under
the prescribed experimental conditions.
3.9. INDUCTION OF NATURAL KILLER ACTIVITY BY TUMOUR ANTIGENS
To investigate whether MBL-2 tumour can generate
natural killer (NK) or NK-like activity in its syngeneic
host, various tumour antigen preparations, including
MMC-treated, sonicated and glutaraldehye-fixed 'MBL-2
cells, were used to immunized the normal mice i.p. three
days before their splenocytes and PEC were harvested and
assayed for NK activity, using 51Cr labelled YAC-1 or
MBL-2 cells as target. For comparison purpose, another
group of normal mice was injected i.v. with 100 pg poly
I:C so as to activate their endogeneous NK activity. It
was found that when YAC-1 cells were used as a target,
injection of various preparations of MBL-2 cells such as
MMC-treated cells, sonicated cells or glutaraldehyde-
fixed cells caused a significant enhancement of NK
activity in the spleen (Table 3.7.) whereas a much lower
level of NK activity was detected in the peritoneal
cavity (Table 3.8.) of mice. Moreover, the levels of
splenic NK activity induced by the tumour antigens were
comparable to that induced by single injection of mice
with an interferon inducer such as poly I:C. On the
other hand, injection of mice with 2 x 105 viable MBL-2
tumour (this dose was chosen because it did not result
in an significant metastatic spread of tumour to the
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Table 3.7. INDUCTION OF NATURAL KILLER (NK) ACTIVITY OF
SPLENOCYTES BY TUMOUR ANTIGENSa











aMice in groups of three were pretreated as described below
and splenocytes were harvested on day 0. NK activity was
assayed by a 4 hr cytotoxic assay using 51Cr-labelled YAC-1
cells as target at effector-to-target ratios of 50: 1 and
100: 1.
UGroup Abbreviations:
C mice with no treatment
PC: mice injected i.v. with 100 µg poly I:C 24 hrs
(day -1) before assay
M: mice were immunized with 2 x 107 mitomycin C-
treated MBL-2 cells i.p. on day -3
S mice were immunized with 107 sonicated MBL-2 cells
i.p. on day -3
G: mice were immunized with 107 glutaraldehyde-treated
MBL-2 cells i.p. on day -3
V: mice were inoculated with 2 x 105 viable MBL-2
cells s.c. on day -3
Statistically different from control group (p< 0.005).
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Table 3.8. INDUCTION OF NATURAL KILLER (NK) ACTIVITY OF
PEC BY TUMOUR ANTIGENSa











a Mice in groups of three were pretreated as described below
and PEC were harvested on day 0. NK activity was assayed by a
4 hr cytotoxic assay using 51Cr-labelled YAC-1 cells as
target at effector-to-target ratios of 50: 1 and 100: 1.
Group Abbreviation:
C mice with no treatment
PC: mice injected i.v. with 100 µg poly I:C 24 hrs (day
-1) before assay
M: mice were immunized with 2 x 107 mitomycin C-
treated MBL-2 cells i.p. on day -3
S mice were immunized with 107 sonicated MBL-2 cells
i.p. on day -3
G mice were immunized with 107 glutaraldehyde-treated
MBL-2 cells i.p. on day -3
V: mice were inoculated with 2 x 105 viable MBL-2
cells s.c. on day -3
C
Statistically significant different from control (p< 0.01).
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spleen or to the peritoneal cavity which may complicate
the NK assay) was found to induce a slight, though
insignificant, elevation of splenic NK activity (Table
3.7.). Interestingly enough, in contrast to YAC-1 cells,
there was little, if any, cytotoxicity detected when
MBL-2 cells were used as a target in this experiment
(Table 3.9. and 3.10.). These results suggest that
although MBL-2 antigens are quite capable of inducing
splenic NK activity, the tumour itself appears to be
insusceptible to NK cell-mediated killing.
3.10.FAILURE TO INDUCE A DELAYED TYPE HYPERSENSITIVITY (DTH)
RESPONSE BY MBL-2 TUMOUR IN VIVO
Table 3.11. demonstrated that sensitization of mice
S.C. with three different doses.(105 -107) of UV-
irradiated MBL-2 cells failed to induce a significant
delayed type hypersensitivity response against the same
tumour when challenged 6 days later as no difference in
footpad thickness was observed between control and test
3.11.GENERATION OF CYTOTOXIC CELLS IN PRIMARY MIXED
LYMPHOCYTE TUMOUR CULTURE (MLTC) IN VITRO
cytotoxic lymphocytes were generated in vitro by
co-culturing normal C57BL/6J mouse splenocytes with
mitomycin C-treated MBL-2 cells (MMC-MBL-2) for 6 days
in RPMI medium supplemented with 10% FCS and 5 x 10-5 M
groups.
68
Table 3.9. INDUCTION OF NATURAL KILLER (NK) ACTIVITY OF
SPLENOCYTES BY TUMOUR ANTIGENSa









aMice in groups of three were pretreated as described below
and splenocytes were harvested on day 0. NK activity was
assayed by a 4 hr cytotoxic assay using 51Cr-labelled MBL-2
cells as target at effector-to-target ratios of 50: 1 and
1 nn
bGroup Abbreviations:
C: mice with no treatment
PC: mice injected i.v. with 100 µg poly I:C 24 hrs
(day -1) before assay
M mice were immunized with 2 x 107 mitomycin C-
treated MBL-2 cells i.p. on day -3
S: mice were immunized with 107 sonicated MBL-2 cells
i.p. on day -3
G: mice were immunized with 107 glutaraldehyde-treated
MBL-2 cells i.p. on day -3
V mice were inoculated with 2 x 105 viable MBL-2
cells s.c on day -3
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Table 3.10. INDUCTION OF NATURAL KILLER (NK) ACTIVITY OF
PEC BY TUMOUR ANTIGENSa









a Mice in groups of three were pretreated as described below
and PEC were harvested on day 0. NK activity was assayed by a
4 hr cytotoxic assay using 51Cr-labelled MBL-2 cells as
target at effector-to-target ratios of 50: 1 and 100: 1.
Group Abbreviations:
C mice with no treatment
PC: mice injected i.v. with 100 pg poly I:C 24 hrs
(day -1) before assay
M: mice were immunized with 2 x 107 mitomycin C-
treated MBL-2 cells i.p. on day -3
S: mice were immunized with 107 sonicated MBL-2 cells
i.p. on day -3
G mice were immunized with 107 glutaraldehyde-treated
MBL-2 cells i.p. on day -3
V mice were inoculated with 2 x 105 viable MBL-2
cells s.c. on day -3
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Table 3.11. FAILURE TO INDUCE A DELAYED TYPE HYPERSENSITIVITY
RESPONSE BY MBL-2 TUMOUR IN VIVO







aMice in groups of five were injected S.C. with either PBS
(Control group) or 105, 106 and 107 UV-irradiated MBL-2
cells for group I, II and III, respectively. Mice were then
challenged with 2 x 105 UV-irradiated MBL-2 tumour injected
S.C. into the right hind footpad and the mean increase in
footpad thickness was measured at 24 and 48 hrs after
challenge.
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2-ME. In one group, interleukin-2 derived from EL-4
lymphoma 'was also added to the culture to a final
concentration of 10% to maximize the proliferative
response. As shown in Table 3.12., splenocytes co-
cultured with tumour alone had a significant killing
activity against MBL-2 target. Furthermore, the activity
of the generated cytotoxic cells was enhanced by the
addition of IL-2 to the MLTC system.
3.12.ANTIGEN SPECIFICITY OF THE PRIMARY EFFECTOR CELLS
GENERATED BY MLTC IN VITRO
The antigen specificity of the primary effector
cells generated by MTLC in vitro was tested using a
panel of targets including YAC-1. P815 and syngeneic
MBL-2 cells.. As shown in Table 3.13., there was
virtually no cytotoxicity towards NK-sensitive YAC-1
target, indicating that the effector cell population
contained little, if there was any, NK cells. On the
other hand, there was a significant, albeit-low, level
of cytotoxicity towards P815 cells, a target that was
known to be susceptible to macrophage-mediated
cytotoxicity. However, the effector cells showed much
higher level of cytotoxicity towards the syngeneic MBL-2
cells, suggesting that there might be some degree of
antigen specificity in the cytotoxic activity of the
nrmarv Pffector cells generated by MTLC in vitro.
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Table 3.12. CYTOTOXICITY OF PRIMARY'MIXED LYMPHOCYTE TUMOUR
CULTURE IN VITRO







aNormal splenocytes of C57BL/6J mice were cultured alone
(group N) or co-cultured with mitomycin C-treated MBL-2
(group NT) or co-cultured with mitomycin C-treated MBL-2 and
10% interleukin-2 (IL-2) in a responder-to-stimulator ratio
of 20: 1 in 75 cm2 culture flasks for 6 days. After the
removal of dead cells and debris by centrifugation on Ficoll-
Isopaque gradient, the viable effector cells were tested for
cytotoxicity in a 8 hr 51Cr release assay using 'MBL-2 as
target.
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Table 3.13. ANTIGEN SPECIFICITY OF THE PRIMARY EFFECTOR CELLS
GENERATED BY MTLC IN VITROa







aNormal C57BL/6J splenocytes were cultured with mitomycin C-
treated MBL-2 cells in complete RPMI medium containing 10%
IL-2. The cells were incubated at 37°C in 75 cm2 culture
flasks in 50 ml volume for 5 days before harvest.
bA 4 hr cytotoxic' assay was carried out with 2 x 104 51Cr-
labelled YAC-1 target cells per well.
A 8 hr cytotoxic assay was carried out with 2 x .104- 51Cr
lasbelled p815 or MBL-2 target cells per well.
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In this chapter, the immunogenicity of MBL-2 tumour and
the induction of host immune responses against this tumour
were investigated. The data showed that mice inoculated with
5 x 106 MBL-2 cells had a MST ranges from 11 to 16 days,
depending on the route of tumour inoculation. Moreover,
micrometastatic spread to other organs (e.g. spleen) was also
observed seven days after tumour inoculation. In contrast,
the metastasic phenomenon was not as rapid if mice were
inoculated with only 2 x 105 MBL-2 cells. Thus, the latter
was selected as the assay model for most experiments since it
represented the early stage of malignant growth. In addition,
the MST of mice injected s.c. or i.p. with 2 x 105 MBL-2
cells (17- 21 days) was long enough for most of the in vivo
assays.
In order to investigate the immunogenicity of MBL-2
tumour, mice were repeatly immunized i.p. with mitomycin C-
treated MBL-2 cells and the results showed that
preimmunization of mice with tumour could significantly
suppress the growth of viable tumour inoculated afterwards.
In other words, the murine MBL-2 tumour is immunogenic in its
syngeneic host. The increase in resistance of the' host to
subsequent challenge with homologous tumour may be due to the
activation of cytotoxic tumouricidal effector cells. This
conclusion was supported by the fact that significant in
vitro cytotoxic activity was exhibited by PEC isolated from
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mice immunized with MMC-MBL-2 cells. Similar phenomenon was
also observed in other tumour systems in mice (Ophir et al.,
1984) and rats (Ibayashi et al., 1985). Besides the induction
of cytotoxic anti-tumour PEC by immunization with inactivated
tumour, the injection of mice in vivo with C. parvum or
picolinic acid could also lead to the generation of anti-
tumour effector cells against MBL-2 tumour in vitro and in
vivo. It was found that C. parvum-activated macrophages
showed a great suppression in the in vivo growth of MBL-2
cells during the first seven days after tumour inoculation
and also induced significant cytotoxic activity against MBL-2
tumour in vitro. On the other hand, picolinic acid-activated
macrophages exhibited strong cytostatic activity against
MBL-2 cells in vitro. However, C. parvum-induced increase in
tumour resistance was found to be only a short term effect
and the life span of tumour-bearing mice was not
significantly increased in comparison to control (data not
shown).. The role of macrophages in defence against MBL-2
tumour was also investigated in macrophage-depleted mice. It
has been reported that silica is highly cytotoxic for
macrophages and all macrophages can be removed by one i.v.
injection of 2 mg of silica (Allison, 1976). If macrophages
were the major effectors against tumours, the depletion of
macrophages would accelerate the growth of tumours and
shorten the life span of mice. However, the present finding
suggested that macrophage-depleted mice had no difference in
MST in comparison to normal MBL-2 tumour-bearing mice and the
macrophage depletion caused no enhancement in the growth of
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MBL-2 tumours. These results appeared to be contradictory
with our earlier observations that activation of macrophages
with agents such as C. parvum or picolinic acid could lead to
the cytolysis and cytostasis of MBL-2 tumour and suggested a
role of macrophages in immune surveillance. However, the
apparent lack of tumour growth enhancement in macrophage-
depleted mice might be due to the regeneration of macrophages
after silica treatment(s) and, therefore, restored the host
immune system against tumour. Thus, the results when taken
together indicated that macrophages could be activated non-
specifically by C. parvum or picolinic acid and such non-
specifically activated macrophages might exhibit a short term
protective effect on MBL-2 tumour growth in vivo and in
vitro.
Natural killer (NK) cell is a type of cytotoxic cell.
that can kill certain tumour targets without prior
sensitization and without major histocompatibility
requirements. It is postulated to be an important effector
cell in the anti-tumour mechanism that is independent of T-
lymphocyte-mediated immunity (Baldwin, 1977 Lotzova, 1985)
and may also play a role in controlling tumour growth and
metastasis (Herberman et al., 1975 Hanna, 1985). In
addition, suppressed NK activity was reported in cancer
patients (De Shazo et al., 1987). Animal studies have
revealed the NK cells as a first-line defence against virus-
infected cells and virus-induced tumour (Minato et al., 1979
Habu et al., 1984). However, in the MBL-2 tumour model, it
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was observed that although various MBL-2 antigen preparations
were quite capable of augmenting the NK activity against YAC-
1 target, yet the MBL-2 tumour itself appeared to be a rather
poor target for NK cell-mediated killing. Moreover, it was
quite interesting to note that viable MBL-2 tumour did not
depress the endogeneous UK activity but instead slightly
augmented its activity in its syngeneic host at an early
stage of tumour development. Nevertheless, from the data
obtained so far, NK killing may not be an important
immunologic mechanism in the surveillance against. MBL-2
tumour.
For many syngeneic or allogeneic tumour systems, delayed
type hypersensitivity (DTH) was strongly proposed to be one
of the major effector mechanisms in the anti-tumour immunity
(Tomita et al., 1981 Kadhim and Barrington-Leigh, 1986).
Moreover, in some transplanted tumour systems, tumour
cytostatic activity induced by lymphokine-producing
lymphocytes and macrophages were assumed to play important
role in tumour rejection (Tomita et al., 1981 Mitani et al.,
1985). The DTH population was suggested to be the same
population as lymphokine-producing lymphocytes. Therefore, in
our study, the DTH response induced by MBL-2 tumour was also
performed. However, MBL-2 could not generate delayed type
hypersensitivity in C57BL/6J mice even though a wide range
of tumour dose was used for sensitization and a high dose of
tumour (up to 1 x 106 cells) was used for challenge. The
apparent lack of DTH response towards MBL-2 tumour indicated
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that T lymphocytes mediating DTH response were not activated
by MBL-2 tumour and might play no role in immune
surveillance. Besides DTH T cells, cytotoxic T cells were
also reported to be the major effector cells in tumour
destruction (Robins and Baldwin, 1985 Robins, 1986). For
adoptive immunotherapy, cytotoxic cells were generated
massively by co-culturing effector cells with specific
stimulator cells in vitro (Grimm, 1986 Shu et al., 1986). In
our study, splenocytes from normal mice were collected and
co-cultured with MMC-treated MBL-2 stimulators and- showed
significant killing against MBL-2 tumour in vitro. The
addition of exogenous IL-2 to cultures enhanced the
cytotoxicity of the generated cells, a result that is in line
with other reports (Cheever et al., 1981 Cheever et al.,
1982 Shu et al., 1986). The antigen specificity of the
generated cells was also tested on a panel of tumour targets.
It is clear that the generated cells showed a very low
cytotoxicity against YAC-1 target indicating that the
cytotoxic cells were unlikely to be NK or NK-like cells.
Although there was some non-specific killing against P815
target, however, the effector cells demonstrated much higher
killing towards the syngeneic MBL-2 target, which strongly
suggested that a specific component might exist in the
primary effector cell population. Nevertheless, the nature of
this specific component has not yet been determined. In other
tumour systems, both cytotoxic T lymphocytes and helper T
lmhoctes were the major effector cells generated in vitro
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and caused the regression of tumours in vivo (Fernandez-cruz
et al., 1982 Taku et al., 1984 Keyaki et al., 1985
Kuribayashi et al., 1985). Another cell type named as LAK
cells may also be generated from the in vitro culture in the
presence of IL-2 (Grimm, 1986). Moreover, LAK cells were
indistinguishable from T lymphocytes in term of surface
markers since both of them expressed OKT-3, OKT-8, Leu-1 and
4F2 (Grimm et al., 1983) and had no universal markers in
comparsion to NK cells. Whether the primary cytotoxic cells
generated in our system were cytotoxic T lymphocytes, helper
T lymphocytes or LAK cells is a mystery and awaits further
investigation.
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In chapter 3, the immunogenicity of MBL-2 tumour in its
syngeneic host was demonstrated. Mice immunized with
mitomycin C-treated MBL-2 cells showed a significant increase
in resistance to subsequent challenge with viable tumour.
Moreover, MBL-2 antigens were found to be capable of
eliciting both non-specific and specific cell-mediated immune
reactions against the tumour. Besides the tumour-induced
immune responses, the dysfunctions of the immune system in
tumour-bearing host are also important factors affecting the
survival of both tumour and host. It has been postulated that
immunosuppression provides a mechanism by which tumours can
use to escape immunologic rejection by their host (Kamo and
Friedman, 1977). A number of reports have indicated that the
mitogenic activity of lymphocytes was suppressed in mice with
progressing tumours (Gillette and Boone, 1975 Hydal et al.,
1985 Roberson and Elgert, 1986). Moreover, the secretion and
responsiveness of various soluble factors, such as
interleukins and MAF, were shown to be depressed in tumour-
bearing mice (Burger and Elgert, 1984 Santos et al., 1985
Roberson and Elgert, 1986). Furthermore, suppressor cells
as well as suppressor factors were also found in tumour-
bearing hosts. It will be of considerable interest to examine
whether the MBL-2 tumour could also induce a similar pattern
of immunological dysfunctions in its syngeneic host arid to
explore how these immunological dysfunctions might influence
the growth and metastasis of tumour.
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In this chapter, different parameters of the immune
functions of the host were monitored during tumour
progression in MBL-2 tumour-bearing mice. The immune
functions that have been assessed included the mitogenic
response of splenocytes, the production of antibody to a T-
dependent antigen (SRBC), the induction of a DTH response to
heterologous erythrocytes, the elicitation of macrophage
migration in vivo and the assay of macrophage function in
vitro. In addition, attempts have also been made to elucidate
the mechanism(s) of tumour-induced immunosuppression by
examining the suppressive effects of cells and soluble
factors derived from MBL-2 tumour-bearing host.
82
R E S U L T S
4.1. MITOGENIC ACTIVITY OF SPLENOCYTES IN TUMOUR-BEARING MICE
T cell mitogens Con A (4 µg/ml), PHA (10 pg/ml) and
B cell mitogens LPS (20 µg/ml) and DS (40 µg/ml) were
used at their pre-determined optimal concentrations to
stimulate the lymphoproliferative response of murine
splenocytes in culture. Splenocytes were obtained from
C57BL/6J mice inoculated with 2 x 105 MBL-2 cells s.c.
3, 6 or 9 days before the removal of spleen. Control
group was treated with 0.5 ml PBS s.c. instead. After
co-culturing the splenocytes with various mitogens
for 48 hrs, each culture well was pulsed with
0.5µ Ci 3H-thymidine and the cells were harvested 6 hrs
later. The 3H-thymidine incorporated by the splenocytes
was expressed as the stimulation index (SI). As shown
in Table 4.1., the responsiveness of splenocytes from
tumour-bearing mice to T cell mitogens (Con A and PHA)
was significantly impaired by day 6 and day 9 but not by
day 3 after tumour inoculation. On the other hand, the
lymphoproliferative response induced by B cell mitogens
(LPS and DS) declined as tumour growth progressed and
significant suppression was only observed by day 9 after
tumour challenge.
4.2. HAEMAGGLUTINATING ANTIBODY TITER AGAINST SRBC IN
TUMOUR-BEARING HOST
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CON A PHA LPS DS
CONTROL 46.72+ 19.35 7.81+ 1.50 67.87+ 14.05 4.84+ 0.90
42.90+ 7.21 12.38+ 4.20 61.30+ 22.46 5.91+ 1.6I
14.14+ 4.13b 4.00+ 1.00b 60.96+ 11.67 3.46+ 1.75II
19.58.+ 1.10 3.66+ 0.64b 33.38+ 7.56b 1.70+ 1.18bIII
aMice in groups of three were inoculated with 2 x 105 MBL-2
cells s.c. on day -3, -6, and -9 for group I. II and III
respectively. For control group, 0.2 ml PBS was injected s.c.
instead. Splenocytes were collected and cultured on day 0.
3H-thymidine incorporation was determined on day +2.
bSignificantly different from control normal mice, p <0.01
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Mice in groups of eight were immunized with
4 x 108 SRBC i.v. to stimulate the production of
antibodies against SRBC. Two test groups were set up in
which mice were inoculated with 2 x 105 MBL-2 cells s.c.
3 or 7 days before immunization. The serum of each mouse
was collected 7 days and 14 days after SRBC
immunization. The antibody titer was determined by the
standard haemagglutination assay. Table 4.2. illustrated
that the circulating haemagglutinating antibody titer
was decreased in tumour-bearing groups, especially in
mice inoculated with tumour 7 days before antigen
injection.
4.3. NUMBER OF PLAQUE-FORMING CELLS AGAINST SRBC IN
TUMOUR-BEARING HOST
Besides measuring the humoral haemagglutinating
antibodies, the number of plaque-forming cells (PFC)
against SRBC in tumour-bearing mice was also determined.
Four groups of mice were set up. One group was
pretreated with PBS whereas the other three groups were
inoculated with 2 x 105 MBL-2 tumour s.c. 4, 6 or 8 days
respectively before receiving an intravenous injection
with SRBC. Their splenocytes obtained 4 days later were
mixed with SRBC and complement in microchamber plates
and then incubated at 37 °C for 1 hr. As shown in Table
4.3., the number of PFC decreased sharply-in tumour-
bearing mice, and significant suppression can be seen at
6 days after tumour inoculation( -50% suppression) and
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DAY 7 DAY 14
CONTRO] 1280+ 0 320+ 80
I 640+ 0 80+ 40
C
II 320+ 160 ND
aC57BL/6J mice in groups of eight were pretreated with PBS in
control group or injected with 2 x 105 MBL-2 tumour s.c. on
day -3 and -7 for group $I and II, respectively. Mice were
immunized with 4- x 10 SRBC i.v. on day 0. Serum was
collected on day +7 and +14.
bThe haemagglutinating antibody titer was expressed as the
reciprocal of the highest dilution of the serum which gave a
positive result of haemagglutination_
Not determined since the mice died out before day +14.
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Table 4.3. NUMBER OF PLAQUE-FORMING CELLS AGAINST SRBC IN
TUMOUR-BEARING HOST
D






aC57BL/6J mice in groups of four were pretreated with PBS for
control animals or inoculated with 2 x 105 MBL-2 tumour s.c.
on day -4, -6 and -8 for group It II and III, respectively.
Mice were immunized with 4 x 108 SRBC i.v. on day 0.
bThe number of plaque-forming cells in spleen of mice were
enumerated on the 4th day after the SRBC immunization using
the modified hemolytic plaque assay (Cunningham and Szenberg,
19hF)
Suppression- x 100
where C: number of plaque-forming cells of the
control group
T: number of plaque-forming cells of the
test group





by day 8, up to 60% suppression of the PFC response was
observed.
1.4. SUPPRESSION OF DTH RESPONSE AGAINST SRBC IN
TUMOUR-BEARING HOST
To investigate the dysfunction in delayed type
hypersensitivity response in tumour-bearing host, mice
were first sensitized with 106 SRBC i.v. and then
challenged with 108 SRBC injected s.c. into the right
hind footpad 4 days later. Footpad swelling was measured
24, 48 and 72 hrs after challenge. Table 4.4.
demonstrated that suppression of the DTH response was
detectable as early as 3 days after tumour inoculation
and this became more pronounced by day 7 when compared
to control.
4.5. PRODUCTION OF INTERLEUKIN-2 IN TUMOUR-BEARING HOST
Splenocytes from normal or tumour-bearing mice were
cultured in RPMI medium containing 5 ug/ml Con A and
5 x 10-5 M 2-ME for 24 hrs and the supernatant was
harvested and tested for IL-2 activity by the
maintenance assay as described by Lafferty et al.
(1980). Fig. 4.1. depicted the IL-2. activity in
different groups. It can be seen that tumour-bearing
groups showed a gradual decline in IL-2 production which
was positively correlated with increasing tumour burden.
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Table 4.4. SUPPRESSION OF DTH RESPONSE AGAINST MBL-2 CELLS
IN TUMOUR-BEARING HOST
MEAN INCREASE IN FOOTPAD THICKNESS(%)
a
GROUP
24 hrs 48 hrs 72 hrs
3.50+ 0.0111.32+ 0.0519.14+ 0.06CONTROL
b
1.72+ 0.03b4.33+ 0.0410.87+ 0.05bI
bb
1.04+ 0.013.65+ 0.043.04+ 0.04bII
.aC57BL/6J mice in groups of six were pretreated with PBS for
control group or injected with 2 x 105 MBL-2 tumour s.c on
day -3 and -7 for group I and II before the sensitization
with 106 SRBC i.v. on day 0. Four days after SRBC
sensitization, each mouse was challenged with 108 SRBC in
50 µl volume injected s.c. into the right hind footpad and
the same volume of PBS was injected into the left hind
footpad as a control. The DTH response was measured 24, 48
and 72 hours after antigen challenge and the results were
expressed as the% mean increase in footpad thickness. As a
negative control, normal unsensitized mice were also
challenged with SRBC and the 24 hr footpad swelling was often
found to be negligible( 5%).
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Fig. 4.1. PRODUCTION OF INTERLEUKI.N-2 IN TUMOUR-BEARING MICE
C57BL/6J splenocytes from mice treated with
PBS (○) or inoculated with 2 x 105 MBL-2' tumour
S.C. for 3 (△), 6() or 9 (☆) days were co-
cultured with Con A (5 ,ug/ml). Culture supernatants
were serially diluted and assayed for IL-2 activity








4.6. EFFECT OF GROWING TUMOUR ON MACROPHAGE MIGRATION IN VIVO
AND MACROPHAGE FUNCTION IN VITRO
It was known that i.p. injection of irritant
substances such as thioglycollate can induce an influx
of macrophages into the peritoneal cavity of mice
(Ogmundsdottir and Weir, 1980). In this experiment, the
effect of progressing tumour growth on the in vivo
migration of macrophages induced by local administration
of sterile thioglycollate was examined. It was found
that there was no appreciable difference in the number
of PEC recovered from tumour-bearing mice as compared to
normal mice under the prescribed experimental conditions
(Table 4.5.). In addition, the phagocytic activity of
the elicited PEC was also unimpaired in tumour-bearing
host (Table 4.5.).
4.7. SUPPRESSOR FACTORS IN THE EXUDATED FLUID AND SERUM
COLLECTED FROM TUMOUR-BEARING HOST
To investigate whether MBL-2 tumour could generate
any immunological suppressive factors in vivo, serum
and/or peritoneal exudated fluid were collected from
mice inoculated with 2 x 105 MBL-2 cells S.C.
or 107 MBL-2 cells i.p. for 7 or 12 days. Serum from
untreated mice was also collected as control serum.
Different dilutions of the collected serum or fluid were
then added to normal mouse splenocytes and the. Mixture
was cultured in RPMI medium containing mitogens Con A,
PHA, LPS or DS for 48 hrs at 37 OC. The 3H-thymidine
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Table 4.5. EFFECT OF GROWING TUMOUR ON MACROPHAGE MIGRATION








aC57BL/6J mice in groups of eight were pretreated with PBS
for control group or inoculated with 2 x 105 MBL-2 cells s.c.
on day -3, -6 and -9 for group I, II and III, respectively.
Each mouse was injected with 2 ml 10% thioglycollate i.p. on
day 0. The number of peritoneal exudated cells (PEC) was
counted 3 days later and the phagocytic activity of PEC was
monitored by the latex uptake assay which was expressed as%
phagocytic index.
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incorporation expressed as net counts per minute (cpm)
was shown in Fig. 4.2. to 4.6.. It was found that the
proliferation of unstimulated lymphocytes was only
affected by the presence of exudated fluid in the
concentration ranged from 2.5% to 10% (Fig. 4.2.). On
the contrary, for the Con A, PHA and DS-activated
cultures, serum or exudated fluid from tumour-bearing
host suppressed thymidine incorporation significantly in
comparison to control in concentrations of 2.5%, 5%
and 10% (Fig. 4.3., 4.4. and 4.6.). However, no
significant difference was observed among LPS-stimulated
cultures (Fig. 4.5.).
4.8. THE PRESENCE OF SUPPRESSOR CELLS IN TUMOUR-BEARING HOSTS
As indicated in section 4.7., suppressive factors
were found to be present in both exudated fluid and
serum collected from tumour-bearing host, it was also
important to examine whether suppressor cells were also
generated in tumour-bearing mice. To demonstrate the
existence of the suppressor cells, splenocytes collected
from mice 7 days after s.c. inoculation of 2 x 105 MBL-2
cells were pretreated with mitomycin-C to inhibit their
growth. Normal splenocytes- from C57BL/6J mice were
cultured alone or co-cultured with MMC-treated
splenocytes in different cell ratios (1: 1, 3: 1, 5:
it 8: 1 and 10: 1 in the presence of T cell mitogen










Fig. 4.2. INHIBITORY ACTIVITY OF SUPPRESSOR FACTORS IN THE
EXUDATED FLUID AND SERUM COLLECTED FROM
TUMOUR-BEARING HOST
A.EFFECT ON UNSTIMULATED CELLS ONLY
Exudated t lulci() and serum() were col iectea
from mice inoculated with 107 MBL-2 tumour i.p.
for 7 days. Serum from mice inoculated with 2
x 105 MBL-2 cells s.c. for 7 days (□) or 12 days
(△) and from control mice() were also
collected. Normal splenocytes were co-cultured
with different dilutions of exudated fluid or serum
in microtiter plate for 48 hrs and then
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Fig. 4.3. INHIBITORY ACTIVITY OF SUPPRESSOR FACTORS IN THE
EXUDATED FLUID AND SERUM COLLECTED FROM
TUMOUR-BEARING HOST
m FPPFrT nN rnu A-ArTTVATF.n T.YMPHOCYTES
Exudated fluid() and serum() were collected
from mice inoculated with 107 MBL-2 tumour i.p.
for 57 days. Serum from mice inoculated with 2
x 10 MBL-2 cells s. c. for 7 days (□) or 12 days
( △) and from control mice() were also
collected. Normal splenocytes were co-cultured
with different dilutions of exudated fluid or serum
in microtiter plate in medium containing Con A
(4 µg/ml) and pulsed with 3H-thymidine after 48 hr
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Fig. 4.4. INHIBITORY ACTIVITY OF SUPPRESSOR FACTORS IN Trig
EXUDATED FLUID AND SERUM COLLECTED FROM
TUMOUR-BEARING HOST
C. EFFECT ON PHA-ACTIVATED LYMPHOCYTES
Exudated fluid() and serum() were collected
from mice inoculated with 107 MBL-2 tumour i.p.
for 57 days. Serum from mice inoculated with 2
x 10 MBL-2 cells s.c. for 7 days (□) or 12 days
(△) and from control mice() were also
collected. Normal splenocytes were co-cultured
with different dilutions of exudated fluid or serum
in microtiter plate in medium containing PHA
(10 µg/ml) and pulsed with 3H-thymidine after 48
















4.5. INHIBITORY ACTIVITY OF SUPPRESSOR FACTORS IN THE
EXUDATED FLUID AND SERUM COLLECTED FROM
TUMOUR-BEARING HOST
D. EFFECT ON LPS-ACTIVATED LYMPHOCYTES
Exudated fluid() and serum() were collected
from mice inoculated with 107 MBL-2 tumour i.p.
for 7 days. Serum from mice inoculated with 2
x 105 MBL-2 cells s.c. for 7 days (□) or 12 days
(△) and from control mice() were also
collected. Normal splenocytes were co-cultured
with different dilutions of exudated fluid or serum
in microtiter plate in medium containing LPS
(20 µg/ml) and pulsed with 3H-thymidine after 48 hr
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Fig. 4.6. INHIBITORY ACTIVITY OF SUPPRESSOR FACTORS IN THE
EXUDATED FLUID AND SERUM COLLECTED FROM
TUMOUR-BEARING HOST
E. EFFECT ON DS-ACTIVATED LYMPHOCYTES
Exudated fluid() and serum() were collected
from mice inoculated with 107 MBL-2 tumour i.p.
for 7 days. Serum from mice inoculated with 2
x 105 MBL-2 cells s. c. for 7 days( □) or 12 days
(△) and from control mice() were also
collected. Normal splenocytes were co-cultured
with different dilutions of exudated fluid or serum
in microtiter plate in medium containing DS
(40 µg/ml) and pulsed with 3H-thymidine after 48 hr
incubation. Cultures were harvested 6 hrs later.
3HTYMIDNEINCORPORATION(102cpm)
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cultures without mitogen, MMC-treated tumour-bearing
mice derived splenocytes only slightly suppressed the
lymphoproliferative response at cell ratios of 1: 1, 3
:1 and 5: 1 (Fig. 4.7.). However, such MMC-treated
splenocytes caused a significant suppression in the
mitogenic transformation of normal splenocytes in both
Con A- and LPS-activated cultures at cell ratios of 1:
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RESPONDER: SUPPRESSOR
CELL RATIO
Fig. 4.7. THE PRESENCE OF SUPPRESSOR CELLS IN
TUMOUR-BEARING MICE
EFFECT ON NORMAL UNSTIMULATED LYMPHOCYTES
Normal splenocytes from C57BL/6J mice were co-
cultured with mitomycin C-treated splenocytes
collected from 7-day MBL-2-bearing mice in cell
ratios of 1: 1, 3: 1, 5: 1, 8: 1, 10: 1 and
1: 0. Splenocytes from MBL-2-bearing mice caused a
slight suppression in the proliferation of normal
lymphocytes in cell ratios of 1: 1, 3: 1, 5: 1











1:1 3:1 5:1 8:1 10:1
RESPONDER: SUPPRESSOR
CELL RATIO
Fig. 4.8. THE PRESENCE OF SUPPRESSOR CELLS IN
TUMOUR-BEARING MICE
EFFECT ON CON A-ACTIVATED NORMAL LYMPHOCYTES
Normal splenocytes from C57BL/6J mice were co-
cultured with mitomycin C-treated splenocytes
collected from 7-day MBL-2-bearing mice in cell
ratios of 1: 1, 3: 1, 5: 1, 8: 1, 10: 1
and 1 0. Splenocytes from MBL-2-bearing mice
caused significant suppressive effect on the
proliferation of Con A-activated lymphocytes,
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RESPONDER: SUPPRESSOR
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Fig. 4.9. THE PRESENCE OF SUPPRESSOR CELLS IN
TUMOUR-BEARING MICE
EFFECT ON LPS-ACTIVATED NORMAL LYMPHOCYTES
Normal splenocytes from C57BL/6J mice were co-
cultured with mitomycin-C treated splenocytes
collected from 7-day MBL-2 bearing mice in cell
ratios of 1: 1, 3: 1, 5: 1, 8: 1, 10: 1
and 1: 0. Splenocytes from MBL-2 bearing mice
caused significant suppressive effect on the
proliferation of LPS-activated lymphocytes,
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In the present investigation, the mitogenic activity or
splenocytes from tumour-bearing mice was compared to that of
the splenocytes collected from normal mice. The results
clearly shown that the mitogenic reactivity of splenocytes
from tumour-bearing host decreased gradually as the time of
tumour-bearing became longer and as the tumour load became
progressively larger. Such unresponsiveness of splenocytes
from tumour-bearing host was also observed in other tumour
systems (Adler et al., 1971 Gillette and Boone, 1973 1975
Roberson and Elgert, 1986). The dysfunction of splenocytes in
terms of mitogenic activity may be due to several factors,
including: (i) the presence of suppressor T cells (Zembala
et al., 1977), B cells (Rudczynski and Mortensen, 1978) or
macrophages (Hydal et al., 1985 Pope, 1985) generated during
tumour growth (ii) the generation of suppressor factors
from host is also a potential means of inducing T-cell
insensitivity to mitogens and (iii) the materials produced by
tumour which may alter the mitogenic properties of
splenocytes. In the present study, the roles of suppressor
cells and suppressor factors derived from the host or tumour
in the inhibition of mitogen-induced lymphoproliferative
response were evaluated. It was found that co-culturing the
normal splenocytes with different ratios of MMC-treated
splenocytes collected from tumour-bearing mice showed a
suppressive effect in their mitogenic reactivity. Such a
suppression may be due to the suppressor cells generated from
103
tumour-bearing host. However, wnetner SUNYLCbDw t
lymphocytes (DiGiacomo and North, 1986 Mukherji et al.,
1986) and/or suppressor macrophages (Hydal et al., 1985
Santos et al., 1985) are involved in the MBL-2-induced
inhibition of lymphoproliferation remains to be established.
Moreover, suppressive factors were also found in the serum
and exudated fluid of tumour-bearing mice and they caused a
significant decline in the mitogen-induced blastogenesis of
normal splenocytes. At this stage, the nature and the
biochemical properties of these suppressive factors are not
yet known. In this context, it has been suggested that
suppressor factors in serum and exudated fluid may originate
from the host or tumour and the nature of these factors is
believed to be the tumour antigens, antibodies generated from
host or the antigen-antibody complexes (Ravikumar et al.,
1984 Leslie, 1985).
Data in this chapter also showed that both the specific
T and B cell responses of the host were suppressed during
MBL-2 tumour growth. Humoral immunity of the host was
affected as the number of antibody-forming cells and the
titer of haemagglutinating antibodies generated against SRBC
were both decreased in tumour-bearing mice when compared to
control. Moreover, inhibition of cell-mediated immunity was
indicated by a depression of the DTH response against SRBC in
mice with tumour. A similar depression of the immune
responses in tumour-bearing hosts were also observed in other
studies (Deegan and Coulthard, 1977; Hilal et al., 1977
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Eskinazi et al., 1985). Indeed, progressive tumour growth in
both humans and experimental animals is often associated with
a generalized immunosuppression which may result from the
complex interactions between tumour and its host. However,
the tumour-induced immunosuppression was not a universal
phenomenon in all tumour-bearing hosts. Some investigators
also reported elevated immune responses in tumour-bearing
hosts (Eskinazi et al., 1985 Saranath et al., 1985). These
contradictory results are not surprising and may be due to
the different characteristics of each tumour type.
Interleukins (ILs) are known to be the important growth
factors in the immune system. In tumour-bearing hosts, the
declined level of ILs and the unresponsiveness of host
towards ILs were reported (Burger and Elgert, 1984 Ayanlar-
Batuman et al., 1986 Walkmann, 1986a and 1986b West et al.,
1986 Yron et al., 1986). In our system, the level of IL-2
produced by splenocytes of MBL-2 tumour-bearing mice was also
decreased in comparison to control group. The decline of IL-2
may be due to the dysfunction of T lymphocytes (Ayanlar-
Butaman et al., 1986 Yron et al., 1986) or lack of IL-1
secretion from macrophages (Santos, 1985). Interleukins were
found to play an essential role in suppressing the binding of
tumours to endothelium by diminishing attachment and
enhancing dissociation (Cohen et al., 1985). Therefore,
lymphokines may be directly or indirectly involved in
interfering the various mechanisms that tumour cells use to
express malignancy. Thus, IL-2 deficiency in tumour-bearing
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lost may also be one of the possible factors that induce the
sapid tumour growth and metastasis.
Macrophages have been known to inhibit the metastasis of
rumours (Filder, 1985) and also play an important role in
inti-tumour mechanism (Alexander, 1976 Cameron and
-*hurchill, 1979 Pace and Russell, 1981 Lovett et al.,
L986). In the present study, although MBL-2 tumour was shown
to induce a generalized immunosuppression of the specific T
and B cell responses in the host, nevertheless, the data also
Showed that the in vivo migration and the in vitro phagocytic
activity of the thioglycollate-elicited macrophages., were
unimpaired in the tumour-bearing host. Collectively, these
findings together with the earlier observation that cytotoxic
and cytostatic macrophages could be generated against MBL-2
tumour raised the possibility that manipulating the functions
of macrophages in tumour-bearing host might be beneficial in
immunotherapy of MBL-2 tumour.
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cancer tnerapy first megan wi.tn tnlee evenLS LirdL
happened at the end of last century. These included the
discovery of X-rays by Wilhelm Konrad Roentgen, the use of
transplantable animal-tumour models in cancer research for
designing new therapeutic methods for human cancers and the
first surgical procedure developed that specifically related
to the metastastic property of cancer (named Halsted radical
mastectomy) (DeVita, 1978). Currently, the three main
modalities for the treatment of cancer are surgery,
chemotherapy and radiotherapy. Since each cancer has its own
characteristic properties, distribution and also pattern of
metastasis, thus no universal therapy can be designed for all
tumours and each therapeutic method has its own unique
advantages and limitations. From the data accumulated so far,
the conventional methods of cancer therapy may cause many
undesirable side effects and the patients often suffered from
a great deal of pain. Therefore, scientists are still
searching for' other therapeutic methods with minimial side
effects in curing cancer. In recent years, there has been
an increasing interest on the use of natural products and
immunomodifiers as a fourth modality or as adjunctive agents
in cancer therapy (Fudenberg and Whitten, 1984 Borden and
Hawkins, 1986). It has been suggested that these synthetic or
natural substances can alter or regulate the interactions
between tumour and host towards therapeutic advantages,
primarily through modulation of host immune response to
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tumour. In this chapter, three different natural products or
immunomodifiers which included gossypol, 'tumour. necrosis
factor-containing serum (TNS) and interleukin-2 (IL-2), were
tested for their ability to inhibit the growth of a murine
syngeneic, transplantable tumour (MBL-2), both in vitro and
in vivo. The preliminary results obtained will be reported
here.
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R E S U L T S
5.1. EFFECT OF GOSSYPOL ON THE GROWTH OF MBL-2 TUMOUR
IN VITRO AND IN VIVO
Gossypol is a natural-occurring compound extracted
from cotton seed and was found to exhibit a broad
spectrum of biological activity including male
antifertility effect (Qian and Wang, 1984), antiviral
property (Wichman et al., 1982) and immunosuppressive
activity (Sein, 1986). Moreover, the work of Tso (1984)
has also shown-that gossypol administered in vivo can
prolong the life span of mice bearing Ehrlich ascites
tumour (EAT), a type of carcinoma that can invade many
different mouse strains. However, whether gossypol can
exert similar anti-tumour activity on the in vivo growth
of a syngeneic murine tumour has not yet been reported.
In this study, the in vitro and in vivo anti-tumour
activity of gossypol on MBL-2 lymphoma will be
evaluated.
To investigate the cytotoxic activity of gossypol,
MBL-2 tumour cells were co-cultured at 37 °C with
various concentrations of gossypol in 0.2 ml complete
RPMI medium for 12 and 24 hrs and cell viability was
measured by the trypan blue dye exclusion method. As
shown in Fig. 5.1., gossypol at low concentrations (10-
20 µM) were found to be cytotoxic to MBL-2 cells at
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Fig. 5.1. CYTOTOXICITY OF GOSSYPOL AGAINST MBL-2 CELLS
IN VITRO
105 MBL-2 cells were co-cultured with different
concentrations of gossypol in vitro. After 12 hr
(▲) and 24 hr (△) incubation, the viability of





hand, higher concentrations (40- 80 p M) of gossypol
were highly cytotoxic to MBL-2 tumour, since there was a
dramatic decline in cell viability both at 12 hrs
and 24 hrs of incubation.
The in vivo anti-tumour activity of gossypol on
MBL-2 cells was studied by comparing the tumour size in
mice injected i.p. with gossypol (6 mg/kg body weight)
daily for 6 consecutive days and in control mice
injected with PBS only. Results in Table 5.1.
demonstrated that there was a' slight
suppression( -30%) of MBL-2 tumour growth in gossypol
treated mice, however, the difference was found to be
statistically insignificant.
5.2. EFFECT OF TUMOUR NECROSIS FACTOR-CONTAINING SERUM (TNS)
ON THE GROWTH OF MBL-2 TUMOUR IN VITRO AND IN VIVO
Tumour necrosis factor (TNF) can be considered as
an anti-cancer cytokine as it can induce necrosis of
certain tumours in vivo and is cytotoxic and/or
cytostatic for many tumour cells in vitro (Carswell et
al., 1975 Hahn et al., 1986). It has been suggested
that the anti-tumour activity of TNF may not be solely
the result of direct cytotoxic effects on the tumour
cells but may be also due to its immunomodulatory
effects in vivo (Palladino and Finkle, 1986). In order
to investigate the therapeutic effect of exogenous TNF
on MBL-2 tumour in mice, it is important to determine
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Table 5.1. EFFECT OF GOSSYPOL ON THE GROWTH OF








aC57BL/6J mice were inoculated with 105 MBL-2 cells i.p. on
day 0. Mice in test group (II) were injected i.p. with 0.5 ml
gossypol diluted in PBS (6 mg/kg) daily whereas mice in
control. group (I) were injected i.p. with an equal volume of
PBS.
bTumour size measured on day 7 was expressed as mean tumour
cell count+ S.E. for groups of 8 mice.
Not statistically different from control group.
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whether TNF is cytotoxic to MBL-2 cells in vitro or can
inhibit the proliferation of MBL-2 tumour in vivo. In
vitro cytotoxic activity of tumour necrosis factor-
containing serum (TNS) was examined by a 51Cr-release
assay using labelled MBL-2 cells as target. Fig. 5.2.
showed that incubation of MBL-2 cells in the presence of
high concentration of TNS (TNS diluted 1:2) caused no
significant killing on 51Cr-labelled MBL-2 cells within 0
to 12 hrs.
The anti-tumour effect of exogenous TNF
administered in vivo was examined using serum containing
TNF. C57BL/6J mice in groups of eight were inoculated
with 2 x 105 MBL-2 cells s.c.. One day later, mice in
the test group were injected with 0.1 ml TNS (titer=
500) daily for 6 consecutive days whereas mice in the
control group were injected with the same volume of
normal serum. Anti-tumour activity was evaluated by
counting the number of MBL-2 cells recoverable from the
peritoneal cavity of mice 7 days post tumour challenge.
As shown in Table 5.2., TNS injection had no significant
anti-tumour activity in vivo under the prescribed
experimental conditions.
5.3. EFFECT OF EXOGENOUS INTERLEUKIN-2 ON THE GROWTH OF
MBL-2 TUMOUR IN VIVO
Interleukin-2 (IL-2) is a lymphokine produced by T







Fig. 5.2. CYTOTOXIC ACTIVITY OF TNS AGAINST MBL-2 IN VITRO
2 x 104 51Cr-labelled MBL-2 cells were cultured in
RPMI medium supplemented with 50% normal serum in
control group. Same number of MBL-2 tumour was
cultured in complete medium containing 50% TNS
in TNS group. It was shown that TNS had no
significant cytotoxic activity against MBL-2







Table 5.2. EFFECT OF EXOGENOUS TNS ON THE GROWTH OF
MBL-2 TUMOUR CELLS IN VIVO
b
TUMOUR COUNT




aC57BL/6J mice were inoculated with 2 x 105 MBL-2 cells i.p.
on day 0. Each mouse was injected with 0.1 ml normal serum in
group I and 0.1 ml TNS in group II from day 1 to 6.
bTumour size measured on day 7 was expressed as mean tumour
count+ S.E. for groups of 8 mice.
cTumour proliferation in vivo was not significantly affected
by exogenous TNS according to the Student's t-test.
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immune responses in vitro and to exert immunomodulatory
activities in vivo (Robb, 1984 Lotze et al., 1985).
These functional effects of IL-2 suggested that IL-2
might have therapeutic potential in the treatment of
cancer. In the present investigation, the inhibitory
effect of exogenous IL-2 on the growth of MBL-2 tumour
in vivo was studied.
IL-2 was produced by in vitro stimulation of a
murine lymphoma cell line EL-4 with phorbol myristate
acetate (PMA) (Farrar et al., 1980) and the resultant
culture supernatant was tested for IL-2 activity by the
maintenance assay (Fig. 5.3.). This IL-2 containing
preparation was injected into tumour-bearing mice daily
for 6 consecutive days after the inoculation of MBL-2
tumour. The tumour size of the IL-2-treated mice was
compared to the control group and the results were shown
in Table 5.3.. It can be seen that culture supernatant
from PMA-stimulated murine lymphoma (EL-4) containing
IL-2 was capable of inhibiting the growth of MBL-2












Fig. 5.3. INTERLEUKIN-2 ACTIVITY OF THE CULTURE SUPERNATANT
OF EL-4 CELLS STIMULATED WITH PMA
IL-2-containing supernatant was produced as
described by Farrar et al. (1980). The IL-2
activity of the supernatant was tested by the
maintenance assay according to Lafferty et al.
(1980). The IL-2 activity of the culture
supernatant of EL-4 cells incubated in the presence
( ▲) or absence() of PMA were depicted in this
figure. In addition, the corresponding stimulation










Table 5.3. EFFECT OF EXOGENOUS INTERLEUKIN-2 ON THE GROWTH







a Mice were inoculated with 2 x 105 MBL-2 cells i.p. on
day 0. Mice in group II were injected i.p. with 0.2 ml
of EL-4 lymphoma-derived IL-2 while same volume of PBS was
injected to mice in group I as control from day 1 to 6.
Tumour size measured on day I was expressed as mean tumour
cell count+ S.E. for groups of 5 mice.
c Significantly different from control group, p< 0.01.
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In this preliminary study, three different natural
products or immunomodifiers, which included gossypol, TNS and
IL-2, were evaluated for their cytotoxic activity against
MBL-2 cells in vitro and/or their inhibitory activity on the
growth of MBL-2 tumour in vivo. Collectively, the data showed
that gossypol was highly cytotoxic to MBL-2 cells in vitro




a yellowish phenolic compound isolated from the seed and root
of cotton plants of the family Malvaciae (Qian and Wang,
19.84) and was widely used as male antifertility drug in
China. In the present study, by using a short term (4 hr)
51Cr release assay, it was found that gossypol did not exert
any immediate cytotoxic effect on MBL-2 cells grown in vitro
(data not shown). However, cytotoxicity of gossypol against
MBL-2 cells was detectable by 12 hrs of incubation and became
more pronounced after 24 hrs of incubation, especially at
higher concentrations of the drug. The present results were
consistent with others who found that gossypol was cytotoxic
to various human and animal cultured cell lines such as
Ehrlich ascites tumour cells (Floridi et al., 1983), Hela
cells and Chinese hamster ovary cells (Wang and Rao, 1984 Ye
et al., 1983), melanoma and colon carcinoma cells (Tuszyski
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and Cossu, 1984). The cytotoxic effect of gossypol may be
attributed to its inhibitory effect on the energy generation
steps of cancer cells (Floridi et al., 1983) by uncoupling
electron transfer from oxidative phosphorylation (Reyes et
al., 1984). In addition, reduced synthesis of DNA, RNA and
protein of the cancer cells were also observed in the
presence of gossypol (Ye et al., 1983 Reyes et al., 1984
Wang and Rao, 1984). Moreover, our data also showed that
gossypol administered at a dose of 6 mg/kg daily for 6 days
did not demonstrate any significant suppressive effect on the
proliferation of MBL-2 cells in vivo, even though it was
found to be highly cytotoxic in vitro. In contrast, similar
treatment with gossypol was found to be effective in
prolonging the life expectancy in mice bearing EAT cells
(Tso, 1984). Our failure to demonstrate a significant anti-
tumour effect of gossypol on MBL-2 tumour growth in vivo may
be due to the fact that administration of gossypol at a dose
of 6 mg/kg daily for 6 consecutive days was not yet
sufficient to lyse the MBL-2 cells in vivo. Alternatively,
some unknown factor (s) secreted from the MBL-2 cells or its
host may render the tumour resistant to the cytotoxic effect
of gossypol in vivo.
Tumour necrosis serum (TNS) was first reported in mid-
1970s and is usually prepared by injecting mice or rabbit
with BCG or C. parvum first and then endotoxin some weeks
later. The blood was collected 1 to 2 hrs after the endotoxin
injection (Playfair et al., 1984). Tumour necrosis factor was
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one of the components in the collected serum and can cause
certain transplanted tumours in mice to necrose or
occassionally to regress completely (Fung et al., 1985 Old,
1985). Recombinant TNF also inhibited effectively the growth
of certain long-term hematopoietic cell lines both in human
and mice (Hahn et al., 1986 Nakano et al., 1986 Sohmura et
al., 1986). In the present study, TNS-was found to have no
significant cytotoxic effect against MBL-2 cells in vitro, as
measured by a short term 51Cr release assay. Whether TNS
could exert any long term or delayed effect on MBL-2 growth
in vitro has not yet been determined. Moreover,
administration of TNS to tumour-bearing mice for 6
consecutive days showed no anti-tumour activity against MBL-2
cells in vivo. In contrast, similar treatment of mice with
TNS markedly suppressed the growth of EAT cells in vivo (Fung
et al., 1985). A likely explanation for these results is that
EAT cells are very sensitive to the cytotoxic effect of TNF
in vitro (Fung et al., 1985) whereas MBL-2 cells are
relatively resistant to its action. The present finding that
TNS has little or no effect on the viability and
proliferative ability of MBL-2 lymphoma cells in vitro and in
vivo is compatible with others who showed that
phenotypically-defined leukemia/lymphoma T and B cells of
human and mouse origin are insensitive to the cytolytic
effect of TNF in vitro (Hahn et al., 1986).
Interleukin-2 is a T cell-derived lymphokine capable of
mediating several important immunologic effects. This
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lymphokine not only able to stimulate the proliferation and
functions of T cells and NK cells but also possesses
macrophage or monocyte-activating properties (Robb, 1984). It
was reported that IL-2 injected into mice markedly enhanced
the tumouricidal activity of splenic cytotoxic T cells and NK
cells (Hefeneider et al., 1983). These observations and
others suggest that IL-2 may be useful in the treatment of
malignant diseases. In the present study, it was found that
local and repeated administration of IL-2-containing culture
supernatant significantly suppressed the growth of MBL-2
tumour in its syngeneic host. Similar tumour-inhibitory
effect of IL-2-containing preparations was observed in other
murine syngeneic tumour systems such as mastocytoma (Paetkau
et al., 1982), methycholanthrene-induced sarcoma (Bubenik et
al., 1985) and melanoma (Herberman, 1986) in mice. Although
the underlying mechanism(s) by which IL-2 might exert its
anti-tumour effect against MBL-2 tumour has not yet been
elucidated, it is conceivable that IL-2 activity might be
mediated through effector mechanisms such as T cells,
macrophages or natural cytotoxic cells (Forni et al., 1985
Lotze et al., 1985 1986 Malkovsky, 1987).
More recently, many reports claimed that the combination
therapy with both lymphokine-activated killer (LAK) cells
and recombinant IL-2 was found to have substantial
therapeutic efficacy in some cancer patients especially those
with advanced metastatic. disease (Mule et al., 1986
Rosenberg, 1985). Therefore, in our further investigation,
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the combination therapy with IL-2 and the adoptive transfer
of tumour-specific cytotoxic cells generated in vitro (as
described in chapter 3) may well provide a more effective
treatment for the MBL-2-bearing host.
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CHAPTER SIX G E N E R A L D I S C U S S 1 0 N
The immunogenicity of MBL-2 tumour was recognized by the
fact that mice immunized with mitomycin-C treated MBL-2 cells
were resistant towards the challenge with-the viable tumour.
In addition, cytotoxic activity against MBL-2 target could
also be generated by in vitro stimulation of normal
splenocytes with MMC-treated MBL-2 tumour. Either cytotoxic
T-lymphocytes (CTL) or lymhokine-activated killer cells (LAK)
may be responsible for such cytotoxic activity. The actual
cell type of these effector cells remains to determined by
studying their surface markers using monospecific antibodies.
Cell-mediated immune mechanisms involving macrophages,
natural killer (NK) cells and' T-lymphocytes may play
different roles in the defence of host against tumour,
depending on host-tumour interactions in different tumour
systems. In the MBL-2 tumour system studied here,
macrophages may play an important role. For instance, the
non-specific C. parvum-activated or picolinic acid-activated
macrophages showed a significant cytotoxic/ cytostatic
activity against MBL-2 cells in vitro. Moreover, the
macrophages may also be a part of the effector cells in the
cytotoxic PEC generated in the pre-immunized mice.
Furthermore, cytotoxic macrophages may also participate in
the protection mechanism against subsequent challenge with
viable MBL-2 tumour in pre.-immunized mice.
Natural killer cells have been reported to be the major
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effector cells against certain tumours (Hanna, 1985 Lotzova,
1985). However, in our study, splenocytes obtained from mice
immunized with various preparations of MBL-2 antigens had an
elevated NK activity against YAC-1 target but not MBL-2
cells. This indicates that MBL-2 antigen(s) can activate NK
cytotoxicity, however, the tumour itself cannot be recognized
or killed by the NK,.effector cells during the cytotoxic
assay. The unresponsiveness of NK cells to MBL-2 target may
be due to the fact that the target antigenic determinants
recognized by NK cells were absent or masked in the MBL-2
tumour. Alternatively, certain suppressive factors might be
secreted by the target cells which inhibit or interfere with
the recognition'step or the cytolytic process of NK cells.
T-lymphocytes including cytotoxic T-lymphocytes, helper
T-lymphocytes and the T-lymphocytes mediating the delayed
type hypersensitivity (DTH) were also reported to be
important in the immune surveillance against tumour. In our
study, the DTH response towards the UV-irradiated MBL-2
tumour was not observed and this indicates that-the DTH T
cells are not the major effector cells in the host
immunologic response to MBL-2 tumour. The roles of the other
T-lymphocyte subpopulations in the anti-tumour mechanisms are
still await further investigation.
The immunodysfunctions induced by the progressively
growing MBL-2 tumour were found in most of the immune
function tested. These included the mitogenic response of
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splenocytes, antibody-producing activity of B-lymphocytes and
the delayed type hypersensitivity response against a T-cell
dependent antigen (SRBC). These dysfunctions in the host
immune system were positively correlated with the duration of
tumour burden, i.e. the longer the tumour burden period was,
the greater the degree of immunosuppression was observed. The
immunosuppression may be due to the presence of suppressive
factors generated by the tumour itself or by the host system
under the influence or control of tumour. As mentioned in
Chapter 5, suppressive factors were found in the peritoneal
exudate fluid and serum.collected from MBL-2 tumour-bearing
mice. The nature of the suppressive factors is unclear,
although they may be the shedded tumour antigens, antibodies
and/or their complexes. Moreover, suppressor cells were also
found in splenocytes of tumour-bearing mice and they
suppressed the mitogenic activity of normal splenocytes. The
nature and specificity of the suppressor cells induced by
MBL-2 tumour is unknown at this stage, although they could be
T-lymphocytes, macrophages and/or B lymphocytes as reported
in other tumour systems. Therefore, in future. work, the
phenotype of these suppressor cells had to be established by
determining their cell surface markers using monospecific
antibodies.
In our preliminary study, three different natural
products including gossypol, interleukin-2 and tumour
necrosis factor-containing serum (TNS) were tested for their
therapeutic efficacy in tumour-bearing host. As shown in our
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data, gossypol could not generate anti-tumour activity
against MBL-2 tumour in vivo even though it was highly
cytotoxic to MBL-2 tumour in vitro. Exogenous interleukin-2
(IL-2) was found to inhibit the MBL-2 tumour growth in vivo
and similar observation was also reported in other tumour
systems (Paetkau et al., 1982). However, another natural
product, TNS, showed no significant direct cytotoxic activity
against MBL-2 in vitro in a 51Cr-release assay. Moreover, TNS
also exhibited no significant anti-tumour activity in vivo
even though a high dose of TNS (0.1 ml, titer= 500) was
injected into tumour-bearing mice for 6 consecutive days.
Whether the strong resistance of MBL-2 tumour towards TNS and
gossypol in vivo is due to any specific factor(s) generated
from the tumour-host interactions has yet to be elucidated.
As shown in this thesis, the immunogenicity of the MBL-2
tumour in its syngeneic host could be demonstrated. However,
the nature of the tumour-specific antigen(s) of the MBL-2
cells is not yet known. In further investigation, the
isolation of TSA from MBL-2 tumour may provide us another
approach to understand the immunological properties of MBL-2
tumour. In our. study, both suppressor cells and suppressive
factors were found. They were believed to be a part of the
mechanism which enables the tumour to escape from
immunological destruction in tumour-bearing host. However,
other controlling factors have not yet been illustrated. More
recently, the genetic components are proposed to be one
major determinant governing the potential tumour growth in a
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host (Klein and Klein, 1985 Ranter et al., 1985 Dulbecco,
1986 Bishop, 1987). Whether the genetic factors also play
any role in the MBL-2 tumour system is still open for
discussion.
In order to evoke a more effective anti-tumour response
to MBL-2 tumour and to overcome the immunosuppression induced
by the tumour, several approaches can be used. Firstly, the
immunogenicity of MBL-2 tumour could be modulated by
enzymatic methods, viral infection, chemical modification or
even changing its lipid composition. Secondly, the host
immune system could also be modulated by various means. For
instance, the use of biological response modifiers (BRM)
which can alter or regulate the interactions between the
tumour and its host towards therapeutic advantages
(Herberman, 1985). Chirigos et al. (1981) claimed-that six
BRM (interferon, MVE-2, PolyICLC, Levan, Mannozym and
Lentinan) effectively activated DTH T cells, NK cells and
macrophage cytostatic activity in MBL-2 tumour-bearing mice
and their effects may be due to their ability to induce
endogenous interferon (IFN). Thus, the use of BRM may also be
a possible therapeutic means for the treatment of cancer.
Moreover, many current reports claimed that the anti-idiotype
antibodies may modulate the immune response and this opens
the way to experimental and therapeutic manipulations of the
immune system (Kennedy et al., 1986). Perhaps the induction
of anti-idiotypic response to tumour may also be another
possible therapeutic approach for the host. Other methods of
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immunotherapy by adoptive transfer of cytotoxic cells and/or
the therapeutic use of different anti-tumour natural
products are also of potential importance. As described in
Chapter 3, macrophages activated by MMC-treated MBL-2 cells
in vivo and cytotoxic cells generated in vitro were both
found to be cytotoxic against MBL-2 target in vitro. The
adoptive transfer of these cytotoxic cells may well be one of
the possible therapeutic approaches as have been emphasised
by other scientists (Rayner et al., 1985 Rosenberg, 1985
Flyer et al., 1986 Itoh et al., 1986 Ortaldo et al.,
1986a). Moreover, combination therapy with both cytotoxic
cells and lymphokines may have greater potential in the
treatment of cancer (Papa et al., 1986 Rosenberg, 1986a).
Recently, infiltrated leukocytes were highly recommended for
generating cytotoxic cells in vitro (Rosenberg, 1986b). Once
the infiltrated lymphocytes could be isolated from the tumour
site, this may also be an attractive approach to cure tumour-
bearing hosts. Lymphokines such as IL-2, IL-1r IFN, MAF and
other lymphotoxins are also suggested to be the possible
candidates for the next generation of immunotherapeutic
agents with less serious side effects and some experimental
and clinical trials had been carried out. Whether these
exogenous lymphokines/lymphotoxins play similar roles as
endogenous lymphokines/lymphotoxins is yet unknown. Perhaps
these exogenous soluble factors may inhibit tumour growth by
some other unknown mechanisms which is also an interesting
topic remain to be elucidated.
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As a conclusion, although the results of this
investigation have raised more questions than they have
answered in the studies of the immunological mechanisms in
the defence of host against MBL-2 tumour growth and
dissemination, yet the present study has pointed out the way
to our future efforts. Undoubtedly, the therapeutic methods
for the treatment of cancer patients are. still expanding and,
obviously, it is still a long way for us to search for
suitable therapies for each cancer. It is hoped that
immunological investigations will continue to make notable
contributions to our understanding of malignant disease.
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